0001211583--12-312024Q2FENCFYes27329000270270000.500.500.200.210.270.4300P1Y0.0150.500.50false0001211583us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001211583us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001211583us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001211583us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001211583us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001211583us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001211583us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001211583us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001211583us-gaap:CommonStockMember2024-04-012024-06-300001211583us-gaap:CommonStockMember2024-01-012024-03-310001211583us-gaap:CommonStockMember2023-04-012023-06-300001211583us-gaap:CommonStockMember2023-01-012023-03-310001211583us-gaap:RetainedEarningsMember2024-06-300001211583us-gaap:AdditionalPaidInCapitalMember2024-06-300001211583us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001211583us-gaap:RetainedEarningsMember2024-03-310001211583us-gaap:AdditionalPaidInCapitalMember2024-03-310001211583us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001211583us-gaap:RetainedEarningsMember2023-12-310001211583us-gaap:AdditionalPaidInCapitalMember2023-12-310001211583us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001211583us-gaap:RetainedEarningsMember2023-06-300001211583us-gaap:AdditionalPaidInCapitalMember2023-06-300001211583us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001211583us-gaap:RetainedEarningsMember2023-03-310001211583us-gaap:AdditionalPaidInCapitalMember2023-03-310001211583us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100012115832023-03-310001211583us-gaap:RetainedEarningsMember2022-12-310001211583us-gaap:AdditionalPaidInCapitalMember2022-12-310001211583us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001211583us-gaap:CommonStockMember2024-06-300001211583us-gaap:CommonStockMember2024-03-310001211583us-gaap:CommonStockMember2023-12-310001211583us-gaap:CommonStockMember2023-06-300001211583us-gaap:CommonStockMember2023-03-310001211583us-gaap:CommonStockMember2022-12-310001211583us-gaap:EmployeeStockOptionMember2024-06-300001211583us-gaap:EmployeeStockOptionMember2024-03-310001211583us-gaap:EmployeeStockOptionMember2023-12-310001211583us-gaap:EmployeeStockOptionMember2023-06-300001211583us-gaap:EmployeeStockOptionMember2023-03-310001211583us-gaap:EmployeeStockOptionMember2022-12-310001211583us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001211583us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001211583us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001211583us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001211583fenc:EquityIncentivePlanMember2024-06-300001211583srt:MinimumMember2024-01-012024-06-300001211583srt:MaximumMember2024-01-012024-06-300001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2024-06-300001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2024-03-310001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2023-12-310001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2023-06-300001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2023-03-310001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2022-12-310001211583srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2024-01-012024-06-300001211583srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2024-01-012024-06-300001211583country:IEfenc:SecondOfficeServiceAgreementMemberfenc:LeaseContingenciesMember2023-08-010001211583fenc:HobokenNewJerseyMemberfenc:OfficeServiceAgreementMemberfenc:LeaseContingenciesMember2020-01-230001211583fenc:OregonHealthAndScienceUniversityAgreementMember2015-05-182024-06-300001211583fenc:BridgeBankMemberfenc:BridgeBankTermLoanMember2022-08-192022-08-190001211583fenc:HobokenNewJerseyMemberfenc:OfficeServiceAgreementMemberfenc:LeaseContingenciesMember2024-01-012024-06-300001211583us-gaap:RetainedEarningsMember2024-04-012024-06-300001211583us-gaap:RetainedEarningsMember2024-01-012024-03-310001211583us-gaap:RetainedEarningsMember2023-04-012023-06-300001211583us-gaap:RetainedEarningsMember2023-01-012023-03-3100012115832023-01-012023-03-310001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberus-gaap:ConvertibleDebtMember2022-08-010001211583srt:MaximumMemberfenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:SubsequentClosingNotesMember2022-09-230001211583fenc:SecuritiesPurchaseAgreementFirstAmendmentMemberfenc:PetrichorOpportunitiesFundIMemberfenc:SubsequentClosingNotesMember2023-12-040001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:SubsequentClosingNotesMember2022-09-230001211583us-gaap:WarrantMember2024-06-300001211583us-gaap:WarrantMember2024-03-310001211583us-gaap:WarrantMember2023-12-310001211583us-gaap:WarrantMember2023-06-300001211583us-gaap:WarrantMember2023-03-310001211583us-gaap:WarrantMember2022-12-3100012115832023-06-3000012115832022-12-310001211583us-gaap:FairValueInputsLevel2Member2024-06-300001211583us-gaap:FairValueInputsLevel2Member2023-12-310001211583us-gaap:MoneyMarketFundsMember2024-06-300001211583us-gaap:FairValueInputsLevel1Member2024-06-300001211583us-gaap:MoneyMarketFundsMember2023-12-310001211583us-gaap:FairValueInputsLevel1Member2023-12-310001211583us-gaap:WarrantMember2024-01-012024-06-300001211583us-gaap:RestrictedStockMember2024-01-012024-06-300001211583us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001211583fenc:RestrictedShareUnitsToPurchaseCommonSharesMember2024-01-012024-06-300001211583fenc:ConvertibleDebtToPurchaseCommonSharesMember2024-01-012024-06-300001211583us-gaap:WarrantMember2023-01-012023-12-310001211583us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001211583us-gaap:WarrantMember2023-01-012023-06-300001211583us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001211583us-gaap:ShareBasedPaymentArrangementEmployeeMember2024-04-012024-06-300001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:RetainedEarningsMember2024-01-012024-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:CommonStockMember2024-01-012024-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMember2024-01-012024-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001211583us-gaap:ShareBasedPaymentArrangementEmployeeMember2023-04-012023-06-300001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:RetainedEarningsMember2023-01-012023-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:CommonStockMember2023-01-012023-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001211583us-gaap:ShareBasedPaymentArrangementEmployeeMember2023-01-012023-03-310001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:ThirdClosingNoteMember2023-12-042023-12-040001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:SecondClosingNoteMember2022-09-232022-09-230001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:FirstClosingNoteMember2022-08-192022-08-190001211583country:IEfenc:SecondOfficeServiceAgreementMemberfenc:LeaseContingenciesMember2024-01-012024-06-300001211583srt:ChiefExecutiveOfficerMemberfenc:ExecutiveSeveranceMember2024-01-012024-06-300001211583fenc:RobertAndradeMemberfenc:ExecutiveSeveranceMember2024-01-012024-06-300001211583fenc:RebatesCustomerFeesCreditsAndCoPayAssistanceMember2024-06-300001211583fenc:ChargebacksDiscountsForPromptPayAndOtherAllowancesMember2024-06-300001211583fenc:RebatesCustomerFeesCreditsAndCoPayAssistanceMember2024-03-310001211583fenc:ChargebacksDiscountsForPromptPayAndOtherAllowancesMember2024-03-3100012115832024-03-310001211583fenc:RebatesCustomerFeesCreditsAndCoPayAssistanceMember2023-12-310001211583fenc:ChargebacksDiscountsForPromptPayAndOtherAllowancesMember2023-12-3100012115832023-12-310001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:ThirdClosingNoteMember2023-12-040001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:SecondClosingNoteMember2022-09-230001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:FirstClosingNoteMember2022-08-190001211583fenc:EquityIncentivePlanMember2024-01-012024-06-300001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:SecondClosingWarrantMember2024-01-012024-06-300001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:FirstClosingWarrantMember2024-01-012024-06-300001211583fenc:TriangleParkNorthCarolinaMemberfenc:LeaseContingenciesMember2024-01-012024-06-300001211583srt:ChiefExecutiveOfficerMemberfenc:ExecutiveSeveranceMember2024-06-300001211583fenc:RobertAndradeMemberfenc:ExecutiveSeveranceMember2024-06-300001211583fenc:PedmarkMember2024-06-300001211583fenc:NorgineLtdMembersrt:MaximumMemberfenc:ExclusiveLicensingAgreementMember2024-03-150001211583fenc:NorgineLtdMemberfenc:ExclusiveLicensingAgreementMember2024-03-150001211583country:IEfenc:OfficeServiceAgreementMemberfenc:LeaseContingenciesMember2024-06-300001211583fenc:NorgineLtdMemberfenc:ExclusiveLicensingAgreementMember2024-01-012024-06-300001211583fenc:NorgineLtdMemberfenc:ExclusiveLicensingAgreementMember2024-06-300001211583fenc:PedmarkMember2024-04-012024-06-300001211583fenc:PedmarkMember2024-01-012024-06-300001211583fenc:PedmarkMember2023-04-012023-06-300001211583fenc:PedmarkMember2023-01-012023-06-300001211583us-gaap:WarrantMember2024-01-012024-06-300001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2024-04-012024-06-300001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2024-01-012024-03-310001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2023-04-012023-06-300001211583us-gaap:RestrictedStockUnitsRSUMemberfenc:EquityIncentivePlanMember2023-01-012023-03-310001211583fenc:RebatesCustomerFeesCreditsAndCoPayAssistanceMember2024-04-012024-06-300001211583fenc:ChargebacksDiscountsForPromptPayAndOtherAllowancesMember2024-04-012024-06-300001211583fenc:RebatesCustomerFeesCreditsAndCoPayAssistanceMember2024-01-012024-03-310001211583fenc:ChargebacksDiscountsForPromptPayAndOtherAllowancesMember2024-01-012024-03-3100012115832024-01-012024-03-3100012115832024-06-300001211583srt:MinimumMemberfenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberfenc:SubsequentClosingNotesMember2022-09-230001211583fenc:OregonHealthAndScienceUniversityAgreementMember2024-01-012024-06-300001211583fenc:LitigationCiplaAndaMember2024-01-012024-06-3000012115832024-04-012024-06-3000012115832023-04-012023-06-300001211583fenc:ProcessaPharmaceuticalsIncMember2024-01-012024-06-3000012115832023-01-012024-06-3000012115832023-01-012023-06-300001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberus-gaap:ConvertibleDebtMember2023-12-310001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberus-gaap:ConvertibleDebtMember2024-06-300001211583fenc:SecuritiesPurchaseAgreementsMemberfenc:PetrichorOpportunitiesFundIMemberus-gaap:ConvertibleDebtMember2024-01-012024-06-3000012115832024-08-0800012115832024-01-012024-06-30xbrli:sharesxbrli:pureiso4217:USDiso4217:USDxbrli:sharesiso4217:EURTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549â€‹FORM 10-Qâ€‹(Mark One)â˜’Â Â Â Â Â Â Â Â Â Â QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2024ORâ€‹â˜Â Â Â Â Â Â Â Â Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from____ to ____â€‹Commission File Number: 001-32295â€‹FENNEC PHARMACEUTICALS INC.(Exact Name of Registrant as Specified in Its Charter)â€‹British Columbia, Canada20-0442384(State or Other Jurisdiction ofIncorporation or Organization)(I.R.S. EmployerIdentification No.)Â Â PO Box 13628, 68 TW Alexander DriveResearch Triangle Park, North Carolina(Address of Principal Executive Offices)27709(Zip Code)â€‹Registrantâ€™s Telephone Number, Including Area Code: (919) 636-4530â€‹Securities registered pursuant to Section 12(b) of the Act:â€‹Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Shares, no par valueFENCNasdaq Capital Marketâ€‹Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YESÂ â˜’Â Â Â Â Â NOÂ â˜â€‹Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YesÂ â˜’Â Â Â Â Â NoÂ â˜â€‹Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.â€‹Large Accelerated FilerÂ Â â˜Â Accelerated Filerâ˜Non-Accelerated Filerâ˜’Â Smaller reporting companyâ˜’Â Â Â Emerging growth companyÂ Â â˜â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â—»â€‹Indicated by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YESÂ â˜Â Â Â Â Â NOÂ â˜’â€‹As of August 8, 2024, there were 27,364,335 of the registrant's common shares outstanding.â€‹â€‹â€‹â€‹Table of Contentsâ€‹â€‹â€‹â€‹Table of ContentsPARTÂ 1: FINANCIAL INFORMATIONItemÂ 1. Financial StatementsFennec PharmaceuticalsÂ Inc.Condensed Consolidated Balance Sheets(U.S. Dollars and shares in thousands)
(Unaudited)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Assetsâ€‹Â Â Â â€‹Â Â â€‹Current assetsÂ â€‹Â Â Â â€‹Â Â â€‹Cash and cash equivalentsâ€‹$ 43,054â€‹$ 13,269â€‹Accounts receivable, netâ€‹â€‹ 12,312â€‹â€‹ 8,814â€‹Prepaid expensesâ€‹Â 4,379â€‹Â 2,575â€‹Inventoryâ€‹â€‹ 2,144â€‹â€‹ 2,156â€‹Other current assetsâ€‹Â 283â€‹Â 44â€‹Total current assetsâ€‹â€‹ 62,172â€‹â€‹ 26,858â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Non-current assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Other non-current assets, net of amortizationâ€‹â€‹ 989â€‹â€‹ 6â€‹Total non-current assetsâ€‹â€‹ 989â€‹â€‹ 6â€‹Total assetsâ€‹$ 63,161â€‹$ 26,864â€‹â€‹â€‹Â Â Â â€‹Â Â Â â€‹Liabilities and stockholdersâ€™ deficitâ€‹Â Â Â â€‹Â Â Â â€‹Current liabilities:â€‹Â Â Â â€‹Â Â Â â€‹Accounts payableâ€‹$ 4,447â€‹$ 3,778â€‹Accrued liabilitiesâ€‹Â 3,038â€‹Â 3,754â€‹Operating lease liability - currentâ€‹â€‹ 12â€‹â€‹ 21â€‹Contract liability - Norgineâ€‹â€‹ 252â€‹â€‹ â€”â€‹Total current liabilitiesâ€‹Â 7,749â€‹Â 7,553â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Long-term liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Term loanâ€‹â€‹ 30,000â€‹â€‹ 30,000â€‹PIK interestâ€‹â€‹ 2,022â€‹â€‹ 1,219â€‹Debt discountâ€‹â€‹ (247)â€‹â€‹ (288)â€‹Contract liability - long-termâ€‹â€‹

24,994â€‹â€‹ 2â€‹Total long-term liabilitiesâ€‹â€‹ 56,769â€‹â€‹ 30,933â€‹Total liabilitiesâ€‹Â 64,518â€‹Â 38,486â€‹â€‹â€‹Â Â Â â€‹Â Â Â â€‹Commitments and contingencies (Note 6)â€‹Â Â Â â€‹Â Â Â â€‹â€‹â€‹Â Â Â â€‹Â Â Â â€‹Stockholdersâ€™ deficit:â€‹Â Â Â â€‹Â Â Â â€‹Common stock, no par value; unlimited shares authorized; 27,329 shares issued and outstanding (2023 â€‘27,027)â€‹Â 145,281â€‹Â 144,307â€‹Additional paid-in capitalâ€‹Â 64,080â€‹Â 62,073â€‹Accumulated deficitâ€‹Â (211,961)â€‹Â (219,245)â€‹Accumulated other comprehensive incomeâ€‹Â 1,243â€‹Â 1,243â€‹Total stockholdersâ€™ deficitâ€‹Â (1,357)â€‹Â (11,622)â€‹Total liabilities and stockholdersâ€™ deficitâ€‹$ 63,161â€‹$ 26,864â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.3Table of ContentsFennec PharmaceuticalsÂ Inc.Condensed Consolidated Statements of Operations(U.S. Dollars and shares in thousands, except per share amounts)(Unaudited)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹JuneÂ 30,Â â€‹JuneÂ 30,Â â€‹JuneÂ 30,Â â€‹Â Â Â 2024Â Â Â 2023Â Â Â 2024Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Revenueâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹PEDMARK product sales, netâ€‹$ 7,262â€‹$ 3,325â€‹$ 14,681â€‹$ 5,002Licensing revenueâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 17,958â€‹â€‹ â€”Total revenueâ€‹â€‹ 7,262â€‹â€‹ 3,325â€‹â€‹ 32,639â€‹â€‹ 5,002â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating expenses:â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Cost of product salesâ€‹â€‹ 608â€‹â€‹ 148â€‹â€‹ 1,158â€‹â€‹ 243Research and developmentâ€‹Â 157â€‹Â 8â€‹Â 160â€‹Â 12Selling and marketingâ€‹â€‹ 4,672â€‹â€‹ 2,340â€‹â€‹ 9,881â€‹â€‹ 4,871General and administrativeâ€‹Â 6,864â€‹Â 5,495â€‹Â 12,736â€‹Â 9,812â€‹â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Total operating expensesâ€‹Â (12,301)â€‹Â (7,991)â€‹Â (23,935)â€‹Â (14,938)(Loss)/income from operationsâ€‹â€‹ (5,039)â€‹â€‹ (4,666)â€‹â€‹ 8,704â€‹â€‹ (9,936)â€‹â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Other (expense)/incomeâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Unrealized foreign exchange (loss)/gainâ€‹â€‹ (17)â€‹â€‹ 5â€‹â€‹ (55)â€‹â€‹ 14Amortization expenseâ€‹â€‹ (23)â€‹â€‹ (73)â€‹â€‹ (43)â€‹â€‹ (145)Unrealized loss on securitiesâ€‹Â â€”â€‹â€‹ â€”â€‹â€‹ (11)â€‹â€‹ (30)Interest incomeâ€‹Â 570â€‹â€‹ 115â€‹â€‹ 767â€‹â€‹ 224Interest expenseâ€‹â€‹ (1,044)â€‹â€‹ (825)â€‹â€‹ (2,078)â€‹â€‹ (1,623)Total other expenseâ€‹Â (514)â€‹Â (778)â€‹Â (1,420)â€‹Â (1,560)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net (loss)/incomeâ€‹$ (5,553)â€‹$ (5,444)â€‹$ 7,284â€‹$ (11,496)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Basic net (loss)/income per common shareâ€‹$ (0.20)â€‹$ (0.21)â€‹$ 0.27â€‹$ (0.43)Diluted net (loss)/income per common shareâ€‹$ (0.20)â€‹$ (0.21)â€‹$ 0.24â€‹$ (0.43)Weighted-average number of common shares outstanding basic â€‹â€‹ 27,297â€‹â€‹ 26,458â€‹â€‹ 27,250â€‹â€‹ 26,471Weighted-average number of common shares outstanding diluted â€‹Â 27,297â€‹Â 26,458â€‹â€‹ 30,354â€‹â€‹ 26,471â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.â€‹4Table of Contentsâ€‹Fennec PharmaceuticalsÂ Inc.Condensed Consolidated Statements of Stockholdersâ€™ Equity (Deficit)ThreeÂ and Six Months Ended June 30, 2024, and 2023(U.S. dollars and shares in thousands)(Unaudited)â€‹Accumulatedâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Additionalâ€‹â€‹â€‹Otherâ€‹TotalÂ â€‹Paid-inâ€‹Accumulatedâ€‹Comprehensiveâ€‹Stockholdersâ€™â€‹Â Â Â Â SharesÂ Â Â Â AmountÂ Â Â Â CapitalÂ Â Â Â DeficitÂ Â Â Â IncomeÂ Â Â Â Equity (deficit)â€‹Balance at DecemberÂ 31,Â 2023â€‹ 27,027â€‹$ 144,307â€‹$ 62,073â€‹$ (219,245)â€‹$ 1,243â€‹$ (11,622)Stock-based compensationÂ - employeesÂ â€”â€‹â€‹ â€”â€‹â€‹ 1,191â€‹Â â€”â€‹Â â€”â€‹Â 1,191Stock option exerciseâ€‹ 75â€‹â€‹ 627â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 627Restricted stock releaseâ€‹ 3â€‹â€‹ â€”â€‹â€‹ (19)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (19)Net incomeÂ â€”â€‹Â â€”â€‹Â â€”â€‹Â 12,837â€‹Â â€”â€‹Â 12,837Balance at MarchÂ 31,Â 2024â€‹ 27,105â€‹â€‹ 144,934â€‹â€‹ 63,245â€‹â€‹ (206,408)â€‹â€‹ 1,243â€‹â€‹ 3,014Stock-based compensationÂ - employeesâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 925â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 925Stock option exerciseâ€‹ 147â€‹â€‹ 347â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 347Restricted stock releaseâ€‹ 77â€‹â€‹ â€”â€‹â€‹ (90)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (90)Net lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (5,553)â€‹â€‹ â€”â€‹â€‹ (5,553)Balance at June 30,Â 2024â€‹ 27,329â€‹$ 145,281â€‹$ 64,080â€‹$ (211,961)â€‹$ 1,243â€‹$ (1,357)â€‹Accumulatedâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Additionalâ€‹â€‹â€‹Otherâ€‹TotalÂ â€‹Paid-inâ€‹Accumulatedâ€‹Comprehensiveâ€‹Stockholdersâ€™â€‹â€‹SharesÂ Â AmountÂ Â Â CapitalÂ Â Â DeficitÂ Â Â IncomeÂ Â Â Equity (deficit)Balance at December 31,Â 2022â€‹ 26,361â€‹$ 142,591â€‹$ 56,797â€‹$ (203,200)â€‹$ 1,243â€‹$ (2,569)Stock-based compensationÂ - employeesÂ â€”â€‹â€‹ â€”â€‹â€‹ 1,089â€‹Â â€”â€‹Â â€”â€‹â€‹ 1,089Stock option exerciseâ€‹ 49â€‹â€‹ 213â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 213Restricted stock releaseâ€‹ 1â€‹â€‹ â€”â€‹â€‹ (20)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (20)Net lossâ€‹ â€”â€‹Â â€”â€‹Â â€”â€‹Â (6,052)â€‹Â â€”â€‹â€‹ (6,052)Balance at MarchÂ 31,Â 2023â€‹ 26,411â€‹â€‹ 142,804â€‹â€‹ 57,866â€‹â€‹ (209,252)â€‹â€‹ 1,243â€‹â€‹ (7,339)Stock-based compensationÂ - employeesâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 2,543â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 2,543Stock option exerciseâ€‹ 95â€‹â€‹ 541â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 541Restricted stock releaseâ€‹ 3â€‹â€‹ â€”â€‹â€‹ (28)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (28)Net lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (5,444)â€‹â€‹ â€”â€‹â€‹ (5,444)Balance at June 30,Â 2023â€‹ 26,509â€‹$ 143,345â€‹$ 60,381â€‹$ (214,696)â€‹$ 1,243â€‹$ (9,727)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.â€‹5Table of ContentsFennec PharmaceuticalsÂ Inc.Condensed Consolidated Statements of Cash Flows(U.S. Dollars in thousands)(Unaudited)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended â€‹â€‹â€‹JuneÂ 30,Â â€‹June 30,Â â€‹â€‹Â Â Â 2024Â Â Â 2023Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash flows provided by (used in):â€‹â€‹Â Â Â â€‹Â Â Â Operating activities:â€‹â€‹Â Â Â â€‹Â Â Â Net income/(loss)â€‹$7,284â€‹$ (11,496)â€‹Adjustments to reconcile net income/(loss) to net cash provided by/(used in) operating activities:â€‹Â â€‹â€‹Â â€‹â€‹Amortization of Norgine assetâ€‹â€‹749â€‹â€‹ â€”â€‹Amortization of debt discountâ€‹â€‹43â€‹â€‹ 32â€‹Gain on securitiesâ€‹â€‹11â€‹â€‹ â€”â€‹Amortization of debt access feesâ€‹Â â€”â€‹Â 113â€‹Unrealized loss on securitiesâ€‹â€‹â€”â€‹â€‹ 30â€‹PIK interestâ€‹â€‹803â€‹â€‹ â€”â€‹Stock-based compensationÂ - employeesâ€‹Â 2,116â€‹Â 3,632â€‹Changes in operating assets and liabilities:â€‹Â â€‹â€‹Â â€‹â€‹Accounts receivableâ€‹â€‹(3,498)â€‹â€‹ (900)â€‹Prepaid expensesâ€‹Â (1,804)â€‹Â 313â€‹Inventoryâ€‹â€‹12â€‹â€‹ (863)â€‹Other current assetsâ€‹Â (255)â€‹Â â€”â€‹Accounts payableâ€‹Â 669â€‹Â 615â€‹Accrued liabilitiesâ€‹Â (716)â€‹Â (999)â€‹Contract liability - Norgineâ€‹â€‹25,246â€‹â€‹ â€”â€‹Net cash provided by (used in) operating activitiesâ€‹Â 30,660â€‹Â (9,523)â€‹â€‹â€‹Â â€‹â€‹Â Â Â â€‹Financing activities:â€‹Â â€‹â€‹Â Â Â â€‹Issuance of shares, options exerciseâ€‹Â 974â€‹Â 754â€‹Cash paid for taxes on restricted share releaseâ€‹â€‹(109)â€‹â€‹ (47)â€‹Deferred issuance costsâ€‹Â (1,740)â€‹Â â€”â€‹Net cash (used in) provided by financing activitiesâ€‹Â (875)â€‹Â 707â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Increase/(decrease) in cash and cash equivalentsâ€‹â€‹29,785â€‹â€‹ (8,816)â€‹Cash and cash equivalents - Beginning of periodâ€‹â€‹13,269â€‹â€‹ 23,774â€‹Cash and cash equivalents - End of periodâ€‹$43,054â€‹$ 14,958â€‹â€‹The accompanying notes are an integral part of these unaudited condensed consolidated financial statement.â€‹â€‹â€‹â€‹â€‹â€‹â€‹6Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹1.Nature of Business and Going Concernâ€‹Fennec PharmaceuticalsÂ Inc., a corporation existing under the laws of British Columbia (â€œFennec,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€), was originally formed under the name Adherex TechnologiesÂ Inc. and subsequently changed its name on SeptemberÂ 3, 2014. Fennec is a commercial stage specialty pharmaceutical company with one U.S. Food and Drug Administration (â€œFDAâ€) approved and European Commission approved product , PEDMARKÂ®, developed to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.Â The Company has four wholly owned subsidiaries: Oxiquant,Â Inc. (â€œOxiquantâ€) and Fennec Pharmaceuticals,Â Inc., both Delaware corporations, Cadherin BiomedicalÂ Inc. (â€œCBIâ€), a Canadian corporation, and Fennec Pharmaceuticals (EU) Limited (â€œFennec Limitedâ€), an Ireland company, collectively referred to herein as the â€œCompany.â€ With the exception of Fennec Pharmaceuticals,Â Inc. and Fennec Pharmaceuticals (EU) all subsidiaries are inactive.These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œUS GAAPâ€) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.During theÂ three and six-month period ended JuneÂ 30, 2024, the Company earned a (loss)/income from operations of $(5,039) and $8,704, respectively.Â At JuneÂ 30, 2024, it had an accumulated deficit of $211,961 and had experienced positive cash flows from operating activities during the six months ended JuneÂ 30, 2024, in the amount of $30,660.On August 1, 2022, the Company entered into a Securities Purchase Agreement (the â€œSPAâ€) with Petrichor Opportunities Fund I LP (the â€œInvestorâ€) in connection with the issuance of up to $45,000 of senior secured floating rate convertible notes (the â€œNotesâ€), issuable in multiple tranches (the â€œNote Financingâ€). On August 19, 2022, the Company closed on the initial tranche of $5,000 (the â€œFirst Closing Noteâ€) which has an Initial Conversion Price equal to $8.11 per share, which was calculated based on a 20% premium of the 5-day volume weighted average price of the Companyâ€™s common shares as traded on the Nasdaq Capital Market (the â€œVWAPâ€) immediately prior to the announcement of the SPA dated August 1, 2022. In connection with the first closing, the Company repaid in full its secured indebtedness with Bridge Bank in the amount of $5,000. On September 23, 2022, the Company closed on the second tranche of the Note Financing in the amount of $20,000 (the â€œSecond Closing Noteâ€), which has an Initial Conversion Price equal to $7.89 per share, which was calculated based on a 20% premium of the 5-day VWAP immediately prior to September 20, 2022, which was the date the Company obtained FDA approval of PEDMARKÂ®. The SPA provided that subsequent to the funding of the Second Closing Note, and before December 31, 2023, the Company could draw up to $20,000 of additional financing under the SPA, in one or more tranches of $10,000 upon mutual agreement of the Company and the Investor (the â€œSubsequent Closing Notesâ€). The Subsequent Closing Notes will be convertible at a price per share equal to $7.89 per share, which price is calculated on the same basis as for the Second Closing Note. A commitment fee of 2.0% of the Notes was payable under the SPA, which was paid by the Company issuing the Investor warrants to purchase 110,996 of the Companyâ€™s common shares (one half issued at the first closing and the other half Â issued at the second closing).The warrants are exercisable at a price per share of $8.11 and have a term of five years from the date of the grant.On December 4, 2023, the Company closed a third tranche under the SPA in the amount of $5,000,000 and issued the Investor a Note in the same amount (the â€œThird Closing Noteâ€) and the Third Closing Note is convertible at a price equal to $7.89 per share, calculated as a 20% premium of the 5-day volume weighted average price of the Companyâ€™s common shares as traded on the Nasdaq Capital Market immediately prior to September 20, 2022, which was the date the Company obtained FDA approval of PEDMARKÂ®.7Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹Also on December 4, 2023, the Company entered into a First Amendment to the Securities Purchase Agreement (the â€œSPA Amendmentâ€) with the Investor, which, among other things, extends the period that the Company may draw the remaining $15,000,000 under the SPA from December 31, 2023, to December 31, 2024. Subsequent draws are subject to mutual agreement of the Company and the Investor and will be represented by Notes that will also be convertible at a price equal to $7.89 per share.On March 17, 2024, the Company announced it had entered into an exclusive licensing agreement with Norgine Pharma UK Limited (â€œNorgineâ€) to commercialize PEDMARQSIÂ® (EU brand name for PEDMARKÂ®) in Europe, New Zealand and Australia. The licensing agreement provided Fennec with approximately $43.2 million up front and may provide Fennec with up to approximately $230 million in milestone and royalty payments in the future. On July 26, 2024, Norgine and Fennec amended the exclusive licensing agreement. The amended agreement maintains all principal payment terms with the primary addition of Norgine assuming responsibility for packaging and labeling of PEDMARQSI.The Company believes current funds provide sufficient funding for the Company to carry out its planned activities, including the continuation of commercialization efforts of PEDMARKÂ®, for at least the next twelve months.These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.â€‹2.Â Â Â Â Significant Accounting PoliciesBasis of PresentationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Companyâ€™s management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited condensed consolidated financial statements and notes filed with the Securities and Exchange Commission (â€œSECâ€) in the Companyâ€™s Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31, 2023. The Companyâ€™s accounting policies are consistent with those presented in the audited consolidated financial statements included in the Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31, 2023. These unaudited interim condensed consolidated financial statements have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts.Use of EstimatesThe preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.Â Significant estimates include revenue recognition, allowance against trade receivables, measurement of stock-based compensation and estimates of the Companyâ€™s capital requirements over the next twelve months from the date of issuance of the consolidated financial statements. Actual results could differ from those estimates..Segment and Geographic InformationOperating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment. As of June 30, 2024, the Company had an operating lease in Ireland which is scheduled to terminate on January 31, 2025. This is the only asset currently located outside of the United States.8Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹Stock-Based CompensationUnder the Companyâ€™s stock-based compensation programs, the Company periodically grants stock options and restricted stock to employees, directors and consultants. The Company also issues shares under an employee stock purchase plan. The fair value of each award is recognized in the Companyâ€™s statements of operations over the requisite service period for such award.The Company uses the Black-Scholes option pricing model to value stock option awards without market conditions, which requires the Company to make certain assumptions regarding the expected volatility of its common stock price, the expected term of the option grants, the risk-free interest rate and the dividend yield with respect to its common stock. The Company calculates volatility using its historical stock price data. Due to the lack of the Companyâ€™s own historical data, the Company elected to use the â€œsimplifiedâ€ method for â€œplain vanillaâ€ options to estimate the expected term of the Companyâ€™s stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate used for each grant is based on the United States Treasury yield curve in effect at the time of grant for instruments with a similar expected life. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends and, at present, has no intention to pay cash dividends.InventoryInventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories mainly include third party manufacturing, logistics and distribution costs. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories. The manufacturing costs for PEDMARKÂ® prior to regulatory approval were not capitalized as inventory but were expensed as research and development costs. The Company expensed pre-launch inventory as it could not reasonably anticipate FDA approval of PEDMARKÂ®.â€‹Revenue RecognitionUnder Accounting Standards Codification (â€œASCâ€) 606, Revenue from Contracts with Customers, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company determines it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customerÍ¾ (ii) identify the performance obligation(s) in the contractÍ¾ (iii) determine the transaction priceÍ¾ (iv) allocate the transaction price to the performance obligation(s) in the contractÍ¾ and (v) recognize revenue when (or as) the Company satisfies its performance obligation(s). As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.License AgreementsThe Company generates revenue from license or similar agreements with pharmaceutical companies for the commercialization of our product. Such agreements may include the transfer of intellectual property rights in the form of licenses. Payments made by the customers may include non-refundable

upfront fees, payments based upon the achievement of defined milestones, and royalties on sales of product.If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the license as revenue upon 9Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹transfer of control of the license. All other promised goods or services in the agreement are evaluated to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. Optional future services where any additional consideration paid to us reflects their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as separate performance obligations.Contingent milestones at contract inception are estimated at the amount which is not probable of a material reversal and included in the transaction price using the most likely amount method. Milestone payments that are not within the Company's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, the Company re-evaluates the probability of achieving development or sales-based milestone payments that may not be subject to a material reversal and, if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.For arrangements that include sales-based royalties, including sales-based milestone payments, and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, revenue is recognized at the later of when the related sales occur or when the performance obligation to which some or all of the royalties have been allocated has been satisfied (or partially satisfied).Costs to Obtain ContractAs the majority of the Company's contracts are short-term in nature, sales commissions are generally expensed when incurred as the amortization period would have been less than one year. These costs are recorded within selling and marketing expenses in the condensed statements of operations. For contracts that extend beyond one year, the incremental expense recognition matches the recognition of related revenue.Net Product RevenueOn September 20, 2022, the FDA approved PEDMARKÂ® in the United States to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. PEDMARKÂ® became commercially available on October 17, 2022. PEDMARKÂ® is the Companyâ€™s first commercial product. Certain specialty distributors of the Company subsequently resell the Companyâ€™s products to health care providers and patients. In addition to distribution agreements with these customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of the Companyâ€™s products. Revenues from product sales are recognized when the customer obtains control of the Companyâ€™s product, which occurs at a point in time, typically upon delivery to the customer.Product Sales Discounts and AllowancesThe Company records revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between the Company and its customers, health care providers, payors and other indirect customers relating to the sales of its products. These reserves are based on the amounts to be claimed on the related sales and are classified as a contra-asset or a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, forecasted customer buying and payment patterns, and the Companyâ€™s historical experience that will develop over time as PEDMARKÂ® and PEDMARQSI (European branded product name) is the Companyâ€™s first commercial product. Overall, 10Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹these reserves reflect the Companyâ€™s best estimates of the amount of consideration to which it is entitled based on the terms of its contracts. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Companyâ€™s estimates. If actual results in the future vary from the Companyâ€™s estimates, the Company will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.Chargebacks: Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist of Public Health Service institutions and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to the Company the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by its contracted customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales by the specialty distributor to its contracted customers.Discounts for Prompt Payment: Customers typically receive a small discount for prompt payment. The Company expects its customers will earn 100% of their prompt payment discounts and, therefore, the Company deducts the full amount of these discounts from total product sales when revenues are recognized.Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. The Companyâ€™s estimates for the expected utilization of rebates are based on customer and payor data received from the specialty distributors and historical utilization rates that will develop over time, as PEDMARKÂ® is the Companyâ€™s first commercial product. Rebates are generally invoiced by the payor and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarterâ€™s shipments to the customers, plus an accrual balance for known prior quartersâ€™ unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust its accruals, which would affect net product revenues in the period of adjustment.Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the third party that administers the copay program.Other Customer Credits: The Company pays fees to its customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to its customers, the Company classifies these payments in selling and marketing expenses in its condensed consolidated statements of operations.Distribution and Other Fees: The Company pays distribution and other fees to certain customers in connection with the sales of PEDMARKÂ®. The Company records distribution and other fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.11Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹The following table summarizes net product revenues for PEDMARKÂ® earned during the three and six months ended June 30, 2024 and 2023, respectively:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Endedâ€‹Six Months Endedâ€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹JuneÂ 30,Â â€‹â€‹JuneÂ 30,Â â€‹â€‹JuneÂ 30,Â In thousandsâ€‹â€‹â€‹2024â€‹â€‹2023â€‹â€‹2024â€‹â€‹2023Product revenues:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Gross product revenues â€‹â€‹$ 9,466â€‹$ 3,711â€‹$ 19,022â€‹$ 5,606Discounts and allowancesâ€‹â€‹â€‹ (2,204)â€‹â€‹ (386)â€‹â€‹ (4,341)â€‹â€‹ (604)Net product revenuesâ€‹â€‹$ 7,262â€‹$ 3,325â€‹$ 14,681â€‹$ 5,002â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the three and six months ended June 30, 2024 and 2023, the Company had three distributors that each represented more than 10% of net sales.The activities and ending allowance balances for each significant category of discounts and allowances for PEDMARKÂ® (which constitute variable consideration) for the six months ended June 30, 2024, was as follows:â€‹Chargebacks,â€‹Rebates, Returns, Customerâ€‹â€‹â€‹â€‹â€‹Discounts forâ€‹Fees/Creditsâ€‹â€‹â€‹â€‹â€‹Prompt pay andâ€‹and Co-Payâ€‹â€‹â€‹In thousandsâ€‹Other allowancesâ€‹Assistanceâ€‹TotalsBalance at December 31, 2023â€‹$ 365â€‹$ 430â€‹$ 795Provision related to sales made in:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Current periodâ€‹Â 352â€‹â€‹ 1,640â€‹â€‹ 1,992Prior periodsâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Payments and customer credits issuedâ€‹â€‹ (497)â€‹â€‹ (104)â€‹â€‹ (601)Balance at March 31, 2024â€‹$ 220â€‹$ 1,966â€‹$ 2,186Provision related to sales made in:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Current periodâ€‹Â 175â€‹â€‹ 2,644â€‹â€‹ 2,819Prior periodsâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Payments and customer credits issuedâ€‹â€‹ (66)â€‹â€‹ (2,614)â€‹â€‹ (2,680)Balance at June 30, 2024â€‹$ 329â€‹$ 1,996â€‹$ 2,325â€‹The allowances for chargebacks, fees due to customers, rebates and discounts for prompt payment are recorded as a contra-asset to accounts receivable, while Medicaid rebates and return allowances are in accrued liabilities in the accompanying condensed consolidated balance sheets.Trade ReceivablesThe Company records gross trade receivables at the time of product sale to its customers. Amounts estimated for the associated chargebacks, cash discounts for prompt payment and any allowances for credit losses are booked as a reserve against accounts receivable and reduction of revenue. The Company Â determines its allowance methodology by pooling receivable balances at the customer level. The Company considers various factors, including loss history, individual credit risk associated to each customer, and the current and future condition of the general economy. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent that any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such a customer. Â Customers in the United States are specialty distributors, and accordingly, the Company considers the risk of potential credit losses to be low. Sales abroad to non-specialty distributors have greater potential for losses. It is the policy of the Company to use a sliding scale to establish a reserve of its gross sales to non-specialty 12Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹distributors, based on aging category. Â The Company had a balance in allowance for credit losses of $2,991 as of June 30, 2024.Cost of Products SoldCost of products sold is related to the Company's product revenues for PEDMARKÂ® and consists primarily of product production costs associated with finished goods inventory and royalties the Company is required to pay to Oregon Health & Science University (â€œOHSUâ€) on all net sales of PEDMARKÂ®. Cost of products sold also consists of shipping and other third-party logistics and distribution costs for PEDMARKÂ®. The Company considered regulatory approval of Â PEDMARKÂ® to be uncertain and product manufactured prior to regulatory approval could not have been sold unless regulatory approval was obtained. As such, the manufacturing costs for PEDMARKÂ® incurred prior to regulatory approval were not capitalized as inventory but were expensed as research and development costs. After FDA approval in September 2022, the Company had various lots of PEDMARKÂ® in various stages of production in connection with the product launch in the fourth quarter of 2022. As of June 30, 2024, the Company capitalized approximately $2.3 million of costs as inventory on the condensed consolidated balance sheet. Of the items capitalized, $0.4 million was capitalized as raw materials, $0.5 million was capitalized as work in process, $1.3 million was capitalized into finished goods, and $1.2 million of that being reclassified to cost of product sold.Cash and Cash EquivalentsCash equivalents consist of highly liquid investments with original maturities at the date of purchase of threeÂ months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment.Â At June 30, 2024, the Company had $43.0 million in cash, savings and money market accounts ($13.3 million at DecemberÂ 31, 2023).Â While the Company has not experienced any loss or write-down of its money market investments, the amounts it holds in money market accounts are substantially above the $0.25 million amount insured by the FDIC and may lose value.Financial InstrumentsFinancial instruments recognized on the balance sheets at June 30, 2024 and December 31, 2023 consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and term loans, the carrying values of which approximate fair value due to their relatively short time to maturity or interest rates that approximate market interest rates. The Company does not hold or issue financial instruments for trading.The Companyâ€™s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. The Company has chosen to avoid investments of a trading or speculative nature to preserve cash.Common Shares and WarrantsAs of June 30, 2024, the Company has 0.2 million warrants with a weighted average strike price of $7.71 outstanding to purchase common shares that have a weighted average life of 3.55 years.13Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹Research and Development Costs and Investment Tax CreditsResearch costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.Concentrations of Credit RiskFinancial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents, and accounts receivable. The Company maintains deposits in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Companyâ€™s investment strategy is focused on capital preservation. The Company invests in instruments that meet the high credit quality standards outlined in the Companyâ€™s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument.The Companyâ€™s trade receivables includes amounts billed to customers for product sales of PEDMARKÂ®. In the U.S., the customers are a limited group of specialty distributors, and accordingly, the Company considers the risk of potential credit losses to be low. The Company also sells to a select group of global distributors. These global distributors are established companies and although the Company regards credit losses with these distributors to be remote, it does recognize the potential for credit losses with this group.Income TaxesThe Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. Â As of June 30, 2024, we maintained a full valuation allowance against our deferred tax assets.The provisions of the Financial Accounting Standards Board (â€œFASBâ€) ASC 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.Foreign Currency TransactionsThe U.S. dollar is the functional currency for the Companyâ€™s consolidated operations. All gains and losses from currency transactions are included in results of operations. Net Income/(Loss) Per ShareBasic net income/(loss) per share is computed by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted net income/(loss) per share is computed using the same method, except the weighted average number of common shares outstanding includes convertible debentures, restricted stock units, stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, warrants to purchase 150 of our common shares, restricted share units to purchase 445 of our common shares and options to purchase 5,228 of our common shares at June 30, 2024, were not included in earnings per share. Such warrants, options and convertible notes 14Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹would have an antidilutive effect. In 2023, warrants to purchase 150 of our common shares and options to purchase 4,887 common shares were excluded from the computation of loss per share as their inclusion would have been antidilutive.Recent Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued amended guidance for improvements to reportable segment disclosures (ASU) No. 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ that requires a public entity disclose significant segment expenses regularly reviewed by the chief operating decision maker (CODM), including public entities with a single reportable segment. The amended guidance is effective for fiscal years beginning January 1, 2024 and interim periods beginning January 1, 2025 and should be applied on a retrospective basis. Early adoption is

permitted. The Company is currently evaluating the effect the adoption of this ASU will have on its consolidated financial statements.In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures,â€ which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. The Company is currently evaluating the effect the adoption of this ASU will have on its consolidated financial statements. On March 21, 2024, the FASB issued Accounting Standards Update (ASU) 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, which provides illustrative guidance to help entities determine whether profits interest and similar awards should be accounted for as share-based payment arrangements within the scope of FASB Accounting Standards Codification (FASB ASC) 718, Compensation-Stock Compensation. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. The Company believes that ASU 2024-01 will not have a material impact on the Companyâ€™s condensed consolidated financial statements.3. Net Income/(Loss) Per Shareâ€‹Net income/(loss) per common share is presented under two formats: basic net income/(loss) per common share and diluted income/(loss) per common share. Basic net income/(loss) per common share is computed by dividing net income/(loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common shares equivalents (e.g. convertible debt, stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of convertible debt, restricted stock units, stock options and warrants. The following table sets forth the computation of basic and diluted net income/(loss) per share (in thousands except per share data):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended JuneÂ 30,Â â€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Numerator:â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â Net income/(loss)â€‹$ (5,553)â€‹$ (5,444)â€‹$ 7,284â€‹$ (11,496)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Denominator:â€‹Â Â â€‹Â Â â€‹Â Â â€‹Â Â Weighted-average common shares, basicâ€‹Â 27,297â€‹â€‹ 26,458â€‹â€‹ 27,250â€‹â€‹ 26,471Dilutive effect of stock optionsâ€‹Â â€”â€‹Â â€”â€‹Â 843â€‹Â â€”Dilutive effect of restricted share unitsâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 445â€‹â€‹ â€”Dilutive effect of warrantsâ€‹Â â€”â€‹Â â€”â€‹Â 11â€‹Â â€”Dilutive effect of convertible debtâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 253â€‹â€‹ â€”Incremental dilutive sharesâ€‹Â â€”â€‹Â â€”â€‹Â 1,552â€‹Â â€”Weighted-average common shares, dilutedâ€‹Â 27,297â€‹Â 26,458â€‹Â 30,354â€‹Â 26,47115Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹Net income/(loss) per share, basic and dilutedâ€‹$ (0.20)â€‹$ (0.21)â€‹$ 0.24â€‹$ (0.43)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹The following common stock equivalents, outstanding convertible debt, options and warrants were excluded from the computation of diluted net income/(loss) per share for the periods presented because including them would have had an anti-dilutive effect:â€‹â€‹â€‹â€‹â€‹â€‹Diluted Earnings Per Shareâ€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Options to purchase common sharesÂ 5,228â€‹ 4,887Convertible debt to purchase common sharesâ€‹ â€”â€‹ â€”Restricted share units to purchase common sharesâ€‹ 445â€‹ â€”Warrants to purchase common sharesÂ 150â€‹ 150â€‹â€‹4.Â Â StockholdersÂ€™ EquityAuthorized Capital StockThe Companyâ€™s authorized capital stock consists of an unlimited number of common shares, no par value per share.Warrants to Purchase Common StockDuring the three and six months ended June 30, 2024 and 2023, there were no warrants issued or exercised. Outstanding warrants have a weighted average life of 3.55 years on June 30, 2024. The following tables detail the Companyâ€™s warrant activity for the three and six months ended June 30, 2024, and 2023, respectively:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Common Sharesâ€‹Â Â Â Â â€‹â€‹Issuable Upon Exerciseâ€‹â€‹â€‹â€‹of Outstandingâ€‹Weighted-AverageInvestor Warrantsâ€‹Warrantsâ€‹Exercise PriceOutstanding DecemberÂ 31,Â 2023Â 150â€‹$ 7.71IssuedÂ â€”â€‹Â â€”Outstanding MarchÂ 31,Â 2024â€‹ 150â€‹$ 7.71Issuedâ€‹ â€”â€‹Â â€”Outstanding JuneÂ 30,Â 2024â€‹ 150â€‹$ 7.71â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Common Sharesâ€‹Â Â Â Â â€‹â€‹Issuable Upon Exerciseâ€‹â€‹â€‹â€‹of Outstandingâ€‹Weighted-AverageInvestor Warrantsâ€‹Warrantsâ€‹Exercise PriceOutstanding DecemberÂ 31,Â 2022Â 150â€‹$ 7.71IssuedÂ â€”â€‹Â â€”Outstanding MarchÂ 31,Â 2023Â 150â€‹Â 7.71Issuedâ€‹ â€”â€‹â€‹ â€”Outstanding JuneÂ 30,Â 2023â€‹ 150â€‹$ 7.71â€‹Equity Incentive PlanThe Compensation Committee of the Board of Directors administers the Companyâ€™s equity incentive plan (the â€œPlanâ€). The Compensation Committee designates eligible participants to be included under the Plan and approves the number of equity instruments to be granted from time to time under the Plan. Currently, the maximum number of equity instruments 16Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹issuable under the Plan, together with the Companyâ€™s prior stock option plan, is twenty-five percent (25%) of the total number of issued and outstanding common shares. Based upon the current shares outstanding, a maximum of 6,825 shares of common stock are authorized for issuance pursuant to stock options or other equity awards granted under the Plan. For all options issued under the Plan, the exercise price is the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of ten years from the date of grant. The Plan allows the issuance of Canadian and U.S. dollar grants. The table below outlines recognized contractor and employee expense from equity awards for the three and six month periods ended June 30, 2024 and 2023.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Endedâ€‹Six Months Endedâ€‹Â Â Â Â June 30,â€‹June 30,â€‹June 30,â€‹June 30,â€‹Â Â Â Â 2024â€‹2023Â Â Â Â 2023â€‹2022Employee options expense recognizedâ€‹$ 925â€‹$ 2,543â€‹$ 2,116â€‹$ 3,632Total option expense recognizedâ€‹$ 925â€‹$ 2,543â€‹$ 2,116â€‹$ 3,632â€‹Stock Option ActivityThe following is a summary of option activity for the three and six months ended June 30, 2024 and 2023. â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹Weighted-AverageOptionsâ€‹OptionsÂ Â Â Exercise PriceOutstanding at DecemberÂ 31,Â 2023â€‹ 4,798â€‹$ 6.27Grantedâ€‹ 45â€‹Â 7.29Exercisedâ€‹ (75)â€‹Â 5.81Forfeitedâ€‹ â€”â€‹â€‹ â€”Outstanding at MarchÂ 31,Â 2024â€‹ 4,768â€‹â€‹ 5.43Grantedâ€‹ 707â€‹â€‹ 7.12Exercisedâ€‹ (147)â€‹â€‹ 2.36Forfeitedâ€‹ (100)â€‹â€‹ 8.00Outstanding at JuneÂ 30,Â 2024â€‹ 5,228â€‹$ 6.48â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Number ofÂ Â Â Weighted-AverageOptionsÂ Â Â Optionsâ€‹Exercise PriceOutstanding at DecemberÂ 31,Â 2022â€‹ 4,539â€‹$ 5.13Grantedâ€‹ 580â€‹Â 8.12Exercisedâ€‹ (49)â€‹Â 4.36ForfeitedÂ (38)â€‹â€‹ 6.98Outstanding at MarchÂ 31,Â 2023â€‹ 5,032â€‹â€‹ 5.43Grantedâ€‹ 125â€‹â€‹ 8.80Exercisedâ€‹ (95)â€‹â€‹ 5.60Forfeitedâ€‹ (175)â€‹â€‹ 7.51Outstanding at JuneÂ 30,Â 2023â€‹ 4,887â€‹$ 5.77â€‹Of the 5,228 options granted and outstanding at June 30, 2024, 3,897 are fully vested and exercisable. Â â€‹17Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹The value of options issued was estimated using the Black-Scholes option pricing model using the assumptions in the table below. The expected volatility was determined using historical volatility of our stock based on the expected term of the award.â€‹â€‹â€‹â€‹â€‹Valuation â€‹â€‹Assumptionsâ€‹Black-Scholes Model Assumptionsâ€‹JuneÂ 30,Â 2024â€‹Expected dividendÂ -%Risk free rateÂ 4.40 - 5.01%Expected volatilityâ€‹45-65%Expected lifeâ€‹1.5 - 6.0yearsâ€‹Restricted Share Units Activityâ€‹The Plan allows for the issuance of restricted share units (â€œRSUsâ€). The following is a summary of RSU activity for the three and six months ended June 30, 2024 and 2023. During the three and six months ended June 30, 2024, there were 21 and 68 RSUs released from restriction, respectively. For the same period in 2023, there were 1 and 17 RSUs forfeited by departing employees. Â Vesting of RSUs vary from one to three years.â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹â€‹Restricted ShareRSUs Current Periodsâ€‹UnitsOutstanding at DecemberÂ 31,Â 2023Â 218AwardedÂ 17Releasedâ€‹ (21)Outstanding at MarchÂ 31,Â 2024â€‹ 214Awardedâ€‹ 299Releasedâ€‹ (68)Forfeitedâ€‹ â€”Outstanding at JuneÂ 30,Â 2024â€‹ 445â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹â€‹Restricted ShareRSUs Past Periodsâ€‹Share UnitsOutstanding at DecemberÂ 31,Â 2022Â 35Awardedâ€‹ 264Releasedâ€‹ (1)Outstanding at MarchÂ 31,Â 2023â€‹ 298Awardedâ€‹ 98Releasedâ€‹ (3)Forfeitedâ€‹ (17)Outstanding at JuneÂ 30,Â 2023â€‹ 376â€‹The value of RSUs issued was estimated using the share price on the date of the award multiplied by the number of common shares granted. â€‹â€‹5.Â Â Â Â Fair Value MeasurementsThe Company has adopted ASC 820, the Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements 18Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:â€‹Level 1: Quoted market prices in active markets for identical assets or liabilities.Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.Level 3: Unobservable inputs that are not corroborated by market data.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Fair Value Measurement at June 30, 2024 and December 31, 2023â€‹â€‹(inÂ thousands)â€‹â€‹QuotedÂ PriceÂ inÂ Activeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Market forÂ Identicalâ€‹SignificantÂ OtherSignificantâ€‹â€‹â€‹â€‹â€‹â€‹Instruments and cash equivalentsâ€‹$ 646(1)Â Â $ 1,340(1)Â Â $ 42,408$ 11,929$ â€"$ â€"$ 43,054$ 13,269Processa common sharesâ€‹$ 6(2)Â Â $ 25(2)Â Â $ â€"$ â€"$ â€"$ â€"$ 6$ 25â€‹(1)The Company held approximately $42.4 million in money market accounts as of June 30, 2024. As of December 31, 2023, the Company held approximately $11.9 million in money market accounts.(2)The Company holds 41 unrestricted common shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), which it received as part of a royalty arrangement in 2020.â€‹6.Â Â Â Â Commitments and ContingenciesOregon HealthÂ & Science University AgreementOn February 20, 2013, Fennec entered into a new exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including PEDMARKÂ® and their use in oncology (the "OHSU Agreement"). OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the licensed technology. On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the OHSU Agreement, which expands Fennec's exclusive license to include the use of N-acetylcysteine as a standalone therapy and/or in combination with PEDMARKÂ® for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product. Certain milestone payments are due upon FDA approval and achievement of sufficient positive EBITDA over a specified period. PEDMARKÂ® received FDA approval in September 2022, however at this time, due to significant uncertainty surrounding timing and magnitude of certain milestones, the Company has only recorded a royalty liability associated with net revenue. The term of the OHSU Agreement as amended by Amendment 1 expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. The Company now has a licensed product with regulatory approval that is covered by the Orphan Drug Designation, the parties amended the term of the agreement. PEDMARKÂ® is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expired in Europe in 2021 and that expire in the United States in 2038. The OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the OHSU Agreement. The Company had accrued approximately $162 in royalty expense to OHSU for the six-month period ended June 30, 2024. Total amount accrued in royalty expense to OHSU as of June 30, 2024 was $399.19Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹LitigationHope Medical Enterprises, Inc. Inter Partes Review (IPR) Challenges On October 29, 2021, Hope Medical Enterprises, Inc. (â€œHopeâ€) filed a Petition for inter partes review (IPR2022-00123) with the Patent Trial and Appeal Board (â€œPTABâ€) of the USPTO to invalidate U.S. Patent No. 10,596,190 (the â€œâ€˜190 Patentâ€), which is exclusively in-licensed from Oregon Health & Science University (â€œOHSUâ€) and relates to a method of using PEDMARKÂ®. The â€˜190 Patent was issued on March 24, 2020. On April 18, 2023, the PTAB invalidated the only claim of theâ€˜190 Patent. Â The final written decision became effective June 20, 2023. Â The â€˜190 Patent was previously listed in the United States Approved Drug Products with Therapeutic Equivalence Evaluations (also known as the â€œOrange Bookâ€). Â In light of PTABâ€™s final written decision on the invalidity of the â€˜190 Patent, we requested that the FDA remove the â€˜190 Patent from the Orange Book. Two United States patent applications claiming priority through the â€˜190 Patent remain pending at the United States Patent and Trademark Office (â€œUSPTOâ€). On October 29, 2021, Hope Medical Enterprises, Inc. (â€œHopeâ€) filed a Petition for inter partes review (IPR2022-00125) to invalidate our wholly owned U.S. Patent No. 10,792,363 (the â€œâ€˜363 Patentâ€), which relates to an anhydrous form of STS and its method of manufacture, which is the active pharmaceutical ingredient in the PEDMARKÂ® product. The â€˜363 Patent was issued October 6, 2020. During the â€˜363 IPR, we disclaimed the patent claims directed to the anhydrous morphic form of STS and continued with claims directed to its method of manufacture. Because the remaining claims in the â€˜363 patent are directed to a method of manufacture, the â€˜363 patent is not eligible for listing in the Orange Book. Â In September 2023, the PTAB issued a Final Written Decision in favor of Fennec and upholding the amended claim.The USPTO has now granted four additional U.S. patents that cover the PEDMARKÂ® formulation and its use, each of which have been, or are in the process of being, listed in the U.S. FDAâ€™s â€œOrange Bookâ€ (U.S. Patent No. 11,291,728 (issued April 5, 2022), U.S. Patent No. 11,510,984 (issued November 29, 2022), U.S. Patent No. 11,617,793 (issued April 4, 2023), and U.S. Patent No. 11,964,018 (issued April 23, 2024)). Â The USPO has also recently Â allowed two additional patent applications (U.S. Patent Application Nos. 17/992,703 and 17/992,707) that cover the use of the PEDMARKÂ® formulation. Â Five additional United States patent applications from this family are pending at the USPTO covering various sodium thiosulfate formulations and uses. We plan to vigorously defend our intellectual property rights to PEDMARKÂ® if challenged. Â An invalidation of our patents covering PEDMARKÂ® could have a material adverse effect on our ability to protect our rights in PEDMARKÂ® beyond periods of marketing exclusivity for PEDMARKÂ® in the United States under Orphan Drug Designation.CIPLA LitigationOn December 1, 2022, we received a letter dated November 30, 2022, notifying us that CIPLA Ltd. and CIPLA USA (â€œCIPLAâ€) submitted to the FDA an ANDA (ANDA No. 218028) for a generic version of PEDMARKÂ® (sodium thiosulfate solution) that contains Paragraph IV Certifications on two of our patents covering PEDMARKÂ®: the OHSU licensedâ€™â€˜190 Patent, expiration date January 2038; and our US 11,291,728 Patent (the â€œâ€™728 Patentâ€), expiration date July 2039. On January 6, 2023, we received a letter dated January 5, 2023, notifying us that CIPLA submitted to the FDA a Paragraph IV Certification on our newly issued US 11,510,984 Patent (the â€œâ€™984 Patentâ€). These patents are listed in FDAâ€™s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for PEDMARKÂ®. The certifications allege these patents are invalid or will not be infringed by the manufacture, use, or sale of CIPLAâ€™s sodium thiosulfate solution.Under the Food and Drug Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, after receipt of a valid Paragraph IV notice, the Company may bring a patent infringement suit in a federal district court against CIPLA within 45 days from the receipt of the Notice Letter and if such a suit is commenced within the 45-day period, the Company is entitled to a 30 month stay on the FDAâ€™s ability to give final approval to any proposed products that reference PEDMARKÂ®. In addition to the 30-month stay, because we have received Orphan Drug Exclusivity, the FDA may not approve CIPLAâ€™s ANDA for at least 7 years from PEDMARKÂ®â€™s FDA approval date of September 20, 2022. 20Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹On January 10, 2023, we filed suit against the CIPLA entities in the United States District Court for the District of New Jersey (Case No. 2:23-cv-00123), for infringement of the â€™190 Patent, the â€™728 Patent, and the â€™984 Patent. Â On April 20, 2023, we filed an Amended Complaint to assert infringement of the â€™728 Patent and the â€™984 Patent. On April 4, 2023, we were granted US 11,617,793 Patent (the â€œâ€™793 Patentâ€) covering the formulation of the PEDMARKÂ® product, which was listed in the Orange Book on or around April 17, 2023, and has an expiration date of July 2039. Â On May 11, 2023, we received written notice of CIPLAâ€™s Paragraph IV Certification as to the â€™793 Patent, which was dated May 10, 2023, along with an enclosed statement of alleged factual and legal bases for stating that the â€™793 Patent is invalid, unenforceable, and/or will not be infringed by CIPLAâ€™s ANDA Product. On July 27, 2023, we filed a Second Amended Complaint to assert the â€˜793 Patent. CIPLA filed an Answer to the Second Amended Complaint on August 31, 2023. On April 23, 2024, we were granted US 11,964,018 Patent (the â€œâ€™018 Patent) covering a method of using our PEDMARKÂ® product to reduce ototoxicity in a patient receiving a platinum based chemotherapeutic for the treatment of a cancer, which was listed in the Orange Book on or around May 8, 2024, and has an expiration date of July 2039. On May 28, 2024, we were granted US 11,992,530 Patent (the â€œâ€™530 Patentâ€) covering a method of using our PEDMARKÂ® product to reduce ototoxicity in a patient receiving a platinum based chemotherapeutic for the treatment of a cancer, which was listed in the Orange Book on or around June 19, 2024, and has an expiration date of July 2039. Â On June 4, 2024, we were granted US 11,998,604 Patent (the â€œâ€™604 Patentâ€) covering a

method of using our PEDMARKÂ® product to reduce ototoxicity in a patient receiving a platinum based chemotherapeutic for the treatment of a cancer, which was listed in the Orange Book on or around June 21, 2024, and has an expiration date of July 2039. Â On June 13, 2024, we filed a Motion for Leave to File a Third Amended Complaint to focus the ANDA litigation against CIPLA on Â the â€™018 Patent and the â€˜793 Patent only. The non-asserted patents remain listed in the Orange Book. On July 22, 2024, CIPLA filed a response indicating that they do not oppose our Motion for Leave to File a Third Amended Complaint. On July 30, 2024, the court granted us leave to file the Third Amended Complaint. On August 1, 2024, we received written notice of CIPLAâ€™s Paragraph IV Certification on the â€™530 Patent and â€™604 Patent.The suit is ongoing. PEDMARQSIÂ® (EU Brand name for PEDMARKÂ®) received European Commission approval in June 2023 and was granted 10 years of market exclusivity in Europe under Pediatric Use (â€œPUMAâ€).Executive SeveranceIn the event of termination of Mr. Raykov's (Chief Executive Officer) employment with the Company other than for cause, the Company will be obligated to pay him a one-time severance payment equal to twelve months of salary (currently $608). In the event of termination of Mr. Andradeâ€™s (Chief Financial Officer) employment with the Company other than for cause, the Company will be obligated to pay him a one-time severance payment equal to six months of salary (currently $220). LeasesThe Company has an operating lease in Research Triangle Park, North Carolina utilizing a small space within a commercial building. The operating lease has payments of $0.4 per month with no scheduled increases. This operating lease is terminable with 30 daysâ€™ notice and has no penalties or contingent payments due. â€‹On January 23, 2020, the Company entered into an Office Service Agreement (the â€œOffice Service Agreementâ€) with Regus to lease office space in Hoboken, New Jersey. Per the terms of the Office Service Agreement, the monthly rent payments are $1. The Company was required to pay a security deposit of Â $2, which is the equivalent to two months of rent. The Office Service Agreement commenced on January 27, 2020, and terminated on July 31, 2020, thereafter the lease has been continuing on a month-to-month basis with either party being able to terminate the agreement by providing one monthsâ€™ advance written notice of termination. â€‹On August 1, 2023, the Company entered into a second Office Service Agreement (the â€œSecond Office Service Agreementâ€) with Regus to lease office space in Dublin, Ireland. Per Â the terms of the Second Office Service Agreement, the monthly rent payments are Â $2. The Company was required to pay a security deposit of $5, which is the equivalent of two monthsâ€™ rent. This lease will terminate on January 31, 2025.21Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹The Second Office Service Agreement commenced on August 1, 2023 and terminates on January 31, 2025, thereafter the lease may continue on a month-to-month basis with either party being able to terminate the agreement by providing one monthsâ€™ advance written notice of termination. The Second Office Service Agreement does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the operating lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate consisting of the current prime rate plus 150 basis points for operating leases that commenced after August 2023. The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹June 30, 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹Remaining lease terms (in months)Â Â Â Â â€‹ 7â€‹Discount rateÂ â€‹ 10%â€‹Â â€‹â€‹â€‹Maturities of lease liabilities as of December 31, 2023 were as follows (in thousands):Â â€‹â€‹â€‹Year Ending December 31,Â â€‹â€‹â€‹2024â€‹$ 10â€‹2025â€‹â€‹ 2â€‹â€‹â€‹â€‹ 12â€‹Less imputed interestâ€‹â€‹ 2â€‹Total lease liabilitiesâ€‹$ 10â€‹â€‹â€‹â€‹â€‹â€‹Current operating lease liabilitiesâ€‹$ 12â€‹Non-current operating lease liabilitiesâ€‹â€‹ -â€‹Total lease liabilitiesâ€‹$ 12â€‹â€‹Employee Benefit Plan â€‹In May 2021, the Company established the Fennec Pharmaceuticals, Inc. 401(k) Plan (the â€œ401(k) Planâ€) for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code of 1986. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. As of June 30, 2024, the Company does not offer matching contributions.â€‹â€‹7.Â Â Â Â Term LoansOn August 1, 2022, the Company entered into the SPA with the Investor in connection with the issuance of up to $45,000 of Notes, issuable in multiple tranches (see Note 1). On August 19, 2022, the Company closed on the initial tranche of $5,000, which has an Initial Conversion Price equal to $8.11 per share, which was calculated based on a 20% premium of the 5-day VWAP immediately prior to the announcement of the SPA. In connection with the first closing, the Company repaid in full its secured indebtedness with Bridge Bank in the amount of $5,000. The Notes become due on the maturity date, which is August 19, 2027.On September 23, 2022, the Company closed on the second tranche of the Note Financing in the amount of $20,000, which has an Initial Conversion Price equal to $7.89 per share, which was calculated based on a 20% premium of the 5-day VWAP immediately prior to the date the Company obtained FDA approval for PEDMARKÂ®.Subsequent to the funding of the Second Closing Note, and before December 31, 2023, the Company may draw up to $20,000 of additional financing under the SPA, in one or more tranches of $10,000 upon mutual agreement of the Company 22Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹and the Investor (the â€œSubsequent Closing Notesâ€). The Subsequent Closing Notes will be convertible at a price per share equal to $7.89 per share, which price is calculated on the same basis as for the Second Closing Note.A commitment fee of 2.0% of the Notes was payable under the SPA, which was paid by the Company issuing the Investor warrants to purchase 110,996 of the Companyâ€™s common shares (one half issued at the first closing and the other half issued at the second closing). The warrants are exercisable at a price per share of $8.11 and have a term of five years from the date of the grant.On December 4, 2023, the Company closed a third tranche under the SPA in the amount of $5,000,000 and issued the Investor a Note in the same amount (the â€œThird Closing Noteâ€) and the Third Closing Note is convertible at a price equal to $7.89 per share, which price was calculated on the same basis as the Second Closing Note. Also on December 4, 2023, the Company entered into the SPA Amendment, which, among other things, extends the period that the Company may draw the remaining $15,000,000 under the SPA from December 31, 2023, to December 31, 2024. Subsequent draws are subject to mutual agreement of the Company and the Investor and will be represented by Notes that will also be convertible at a price equal to $7.89 per share.Cash interest on outstanding principal shall accrue at a rate of prime, plus 4.5% per annum, from the date of funding (13% at June 30, 2024 and 13% as of December 31, 2023). Cash interest is due on the first business day of each calendar quarter (â€œInterest Dateâ€). Payment-inkind (â€œPIKâ€) interest will commence on funding date and accrue at a rate of 3.5% per annum. PIK interest will stop accruing on August 24, 2024. Any accrued PIK interest shall remain outstanding and be payable on each Interest Date and be added to the outstanding principal amount. The Company has accrued $1.6 million in PIK interest and has classified the PIK interest in long-term liabilities.The Notes are convertible into fully paid, non-assessable shares of the Companyâ€™s common shares at any point after their issuance dates and before the maturity date. Any amount of the Notes may be converted into common shares so long as it does not create partial shares. The conversion rate is determined by dividing the conversion amount by the conversion price. Provisions of the SPA create legal, valid and enforceable liens on, and security interests in, all of the Companyâ€™s and each of its subsidiariesâ€™ assets.Aggregate annual payments due on the SPA as of June 30, 2024 are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹Years Ending December 31,Â Â Â Â Â â€‹Amount2024Â $ â€”2025â€‹â€‹ â€”2026â€‹â€‹ â€”2027â€‹â€‹ 30,000Payment in kind interestâ€‹â€‹ 2,022Total future paymentsâ€‹â€‹ 32,022Less: unamortized debt discountâ€‹â€‹ (247)Total term loan, net of debt discountâ€‹$ 31,775â€‹In the event of default or change of control, all unpaid principal and all accrued and unpaid interest amounts (if any) become immediately due and payable. Events of default include, but are not limited to, a payment default, a material adverse change, and insolvency. The SPA facility is secured by all of the Companyâ€™s assets, including all capital stock held by the Company.Debt issuance costs of $175 were paid in cash for legal fees and to the Investor in 2022 and warrants valued at $441 were granted to the Investor to secure access to the SPA. These amounts were capitalized and are being amortized over the access period of the SPA. Upon drawing tranche 1 through 3, the Company recorded a debt discount of $314, which was 23Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹based on a pro-rata allocation of the issue costs to secure the SPA, reducing the capitalized amount by the same amount. The debt discount is being amortized over the life of the SPA.â€‹8. Â License AgreementLicense Agreement with Norgine Pharma UK LimitedOn MarchÂ 17, 2024, the Company announced that, through its wholly-owned subsidiary, Fennec Pharmaceuticals,Â Inc. entered into a License and Supply Agreement (the â€œAgreementâ€) with Norgine Pharma UK Limited (â€œNorgineâ€), pursuant to which Norgine is granted an exclusive license to commercialize the Companyâ€™s product PEDMARQSIÂ® (known as PEDMARKÂ® in the United States) for all human indications in the European Economic Area, Switzerland, the United Kingdom, Australia and New Zealand (collectively, the â€œTerritoryâ€). On July 26, 2024, Norgine and Fennec amended the exclusive licensing agreement. The amended agreement maintains all principal payment terms with the primary addition of Norgine assuming responsibility for packaging and labeling of PEDMARQSI.Â Pursuant to the terms of the Agreement, Fennec shall receive the following payments from Norgine: (i)Â an upfront payment in the amount of â¬40 million or approximately $43.2 million, which was paid to Fennec on MarchÂ 15, 2024, (ii)Â up to â¬210 million (or approximately $230 million) upon the achievement of certain regulatory and commercial milestones, and (iii)Â tiered royalty payments based on net sales of PEDMARQSIÂ® in the Territory, which royalty payment range from mid-teen percent to mid-twenty percent based on the aggregate net sales of PEDMARQSIÂ® in the Territory. The tiered royalty payments are subject to material reduction if an alternative or generic version of PEDMARQSIÂ® becomes available in any respective country or jurisdiction within the Territory.Â Subject to customary rights of each party to earlier terminate the Agreement, the term of the Agreement continues for the longer of: (i)Â MarchÂ 15, 2034, or (ii)Â with respect to any particular country in the Territory, (a)Â the expiration of regulatory market exclusivity for PEDMARQSIÂ® in such country, or (b)Â the last-to-expire of all patents for PEDMARQSIÂ® in such country. The term of the Agreement shall be automatically renewed for additional three-year periods unless either party provides the other party written notice of its intent not to renew the Agreement at least one year prior to the applicable termination date of the Agreement.The Company evaluated the Agreement under ASC 606 and concluded that Norgine represents a customer in the transaction. Â There were two performance obligations: a license of functional IP and a material right for future supply. The Company will allocate the transaction price, including currently unrecognized variable consideration, to the two performance obligations based on estimated standalone selling price, which was estimated using projected cash flows. The initial transaction price consisted of the non-refundable upfront payment, a portion of which was allocated to and recognized as License Revenue in the first quarter of 2024 as the requirements for revenue recognition under ASC 606 were met. The portion of the transaction price associated with the material right is deferred and reflected as deferred revenue in the condensed consolidated balance sheets. Deferred revenue associated with the material right is recognized as contract liabilities under the supply arrangement are made. The remaining forms of consideration are variable because they are dependent on the achievement of sales-based or other milestones. The Company evaluated the constraint on variable consideration and concluded that the milestone payments are dependent on regulatory approvals and actions of third parties, and thus are highly susceptible to factors outside the Companyâ€™s influence. Therefore, at contract inception, the milestones are not included in the transaction price as it is not probable that a significant reversal of revenue would not occur. Sales-based milestones will be recognized as revenue or deferred as part of the material right in the period when the related sales threshold is met. All other milestones will be recognized as revenue or deferred as part of the material right immediately in the period the underlying milestone is achieved. Any consideration related to sales-based royalties will be recognized as revenue or deferred as part of the material right when the related sales occur. For the six months ended June 30, 2024, the Company did not recognize any milestone or royalty revenue payments from Norgine sales of PEDMARQSIÂ® pursuant to the Agreement.In conjunction with entering into the Agreement, the Company paid approximately $1.7 million in incremental costs, which were capitalized and recorded within other non-current assets. Â The Company amortizes the asset over the period of 24Table of ContentsFennec Pharmaceuticals Inc. Notes to the Unaudited Interim Condensed Consolidated Financial Statements (U.S. dollars and shares in thousands, except per share information)â€‹expected benefit using a systematic basis that reflects the pattern of transfer to the customer. A portion that represents the license was recognized immediately and is recorded within selling and marketing expense in the condensed consolidated statements of operations. As of June 30, 2024, $0.97 million in incremental cost was capitalized. â€‹9.Â Â Â Â Subsequent EventsOn July 26, 2024, the Agreement with Norgine was amended and restated, pursuant to which Norgine assumed responsibility for packaging and labeling of PEDMARQSI for the Territory.â€‹On August 5, 2024, the Company announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennecâ€™s strategic direction for operational success in the expansion of PEDMARKÂ® use in community oncology and the adolescent and young adult (AYA) population. Mr. Raykov will remain on Fennecâ€™s Board of Directors and will no longer serve as CEO upon Jeff Hackmanâ€™s appointment.â€‹â€‹â€‹25Table of ContentsItem 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.Caution Concerning Forward-Looking StatementsThe following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 29, 2024 (the â€œAnnual Reportâ€) and our unaudited interim condensed consolidated financial statements and related notes appearing in this Quarterly Report on Form 10-Q (the â€œQuarterly Reportâ€). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to the Companyâ€™s plans and strategy for its business, includes forward looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can be identified by words such as â€œfuture,â€ â€œanticipates,â€ â€œbelieves,â€ â€œestimates,â€ â€œexpects,â€ â€œintends,â€ â€œplans,â€ â€œpredicts,â€ â€œwill,â€ â€œwould,â€ â€œcould,â€ â€œcan,â€ â€œmay,â€ and similar terms. Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements. As a result of many factors, including those factors set forth in Part I, Item 1A of the Annual Report under the heading â€œRisk Factorsâ€, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.The following discussion should be read in conjunction with our Annual Report and the condensed consolidated financial statements and accompanying notes included elsewhere in this report.OverviewWe are a commercial-stage biopharmaceutical company focused on our only product PEDMARKÂ®. On September 20, 2022, we received approval from the US Food and Drug Administration (â€œFDAâ€) for PEDMARKÂ® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. This approval makes PEDMARKÂ® Â the first and only treatment approved by the FDA in this area of unmet medical need. Â On October 17, 2022, we announced commercial availability of PEDMARKÂ® in the U. S. In addition, in January 2023, PEDMARK was included in the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for Adolescent and Young Adult (AYA) Oncology with a category 2A recommendation.In June 2023, we received European Commission Marketing Authorization for PEDMARQSITM (known as PEDMARKÂ® in the U.S.) Further, the decision included the receipt of a Pediatric Use Marketing Authorization (â€œPUMAâ€) in the European Union (â€œEUâ€) with up to 10Â years of data and market protection. Â The Company in conjunction with Norgine is currently preparing for an EU launch of PEDMARQSITM in the fourth quarter of 2024.In the U.S., we sell our product through an experienced field force and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and our programs supporting patient access to PEDMARKÂ®. Now that we have obtained applicable regulatory approval to sell PEDMARKÂ® in the U.S. and authorization from the European Commission Marketing Authorization for PEDMARQSITM in the EU, we recognize there may still be a need to establish collaborations that provide us with up-front payments, licensing fees, milestone payments, royalties, or other revenue.Further, we have established Fennec HEARSâ„¢, a comprehensive single source program designed to connect PEDMARKÂ® patients to both patient financial and product access support. The program offers assistance and resources, regardless of insurance type, that can address co-pays or lack of coverage when certain eligibility requirements are met. Fennec HEARSâ„¢ also provides access to care coordinators that can answer insurance questions about coverage for PEDMARKÂ® and provide tips and resources for managing treatment. Â We received Orphan Drug Exclusivity for PEDMARKÂ® in January 2023, which provides seven years of market exclusivity from its FDA approval on September 20, 2022 until September 20, 2029. We currently have five patents listed for PEDMARKÂ® in the FDAâ€™s Orange Book. In September 2022, the USPTO issued Patent No. 11,291,728 (the â€œUS â€˜728 26Table of ContentsPatentâ€), in December 2022, the USPTO issued Patent No. 11,510,984 (â€œUS â€˜984 Patentâ€) and in April 2023, the USPTO issued Patent No. 11,671,793 (â€œUS â€˜793 Patentâ€) that covers PEDMARKÂ® pharmaceutical formulation. Further, US 11,964,018 Patent (the â€œâ€™US 018â€™ Patent) and US 11,992,530 Patent (the â€œUS â€™530 Patentâ€) covering methods of using our PEDMARKÂ® product to reduce ototoxicity in a patient receiving a platinum based chemotherapeutic for the treatment of a cancer. The US â€˜728 Patent, US â€˜984 Patent, US â€˜793. US â€˜018 and USâ€™530 patents will expire in 2039. We are also pursuing additional patent applications in both the U.S. and internationally for PEDMARKÂ®. PEDMARKÂ® Product OverviewPEDMARKÂ® is the first and only therapy approved by the FDA indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. Further,

PEDMARQSITM, known as PEDMARKÂ® in the U.S., was granted marketing authorization by the European Commission in June 2023. Â PEDMARKÂ® Â is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARKÂ® is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (â€œCOGâ€) Protocol ACCL0431 and SIOPEL 6.In the U.S. and Europe, it is estimated that more than 10,000 children annually may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.PEDMARKÂ® has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.Cisplatin Induced OtotoxicityCisplatin and other platinum compounds are essential chemotherapeutic agents for the treatment of many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to the survivors of pediatric cancer.The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time. Infants and young children that are affected by ototoxicity at critical stages of development lack speech and language development and literacy, and older children and adolescents often lack social-emotional development and educational achievement.27Table of ContentsResults of OperationsThree months ended June 30, 2024 versus three months ended June 30, 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Â Â Â Â â€‹Three Months Ended â€‹Â Â Â Â â€‹â€‹â€‹In thousands of U.S. DollarsÂ Â Â Â JuneÂ 30,Â 2024Â Â Â Â %Â Â Â Â Â Â JuneÂ 30,Â 2023Â Â Â Â %Â Â Â Â Â Â ChangeÂ Â Â Â PEDMARK product sales, netâ€‹$ 7,262â€‹â€‹â€‹$ 3,325â€‹â€‹â€‹$ 3,937â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating expenses:â€‹Â â€‹Â Â Â â€‹Â â€‹Â Â Â â€‹Â â€‹â€‹Cost of product salesâ€‹â€‹ 608â€‹ 5%Â Â â€‹ 148â€‹ 2%Â Â â€‹ 460â€‹Research and developmentâ€‹Â 157Â 1%Â Â Â 8Â â€”%Â Â Â 149â€‹Selling and marketingâ€‹â€‹ 4,672â€‹ 38%Â Â â€‹ 2,340â€‹ 29%Â Â â€‹ 2,332â€‹General and administrationâ€‹Â 6,864Â 56%Â Â Â 5,495Â 69%Â Â Â 1,369â€‹Total operating expenseâ€‹Â 12,301Â 100%Â Â Â 7,991Â 100%Â Â Â 4,310â€‹Loss from operationsâ€‹Â (5,039)Â Â Â â€‹Â (4,666)Â Â Â â€‹Â (373)â€‹Amortization expenseâ€‹Â (23)Â Â Â â€‹Â (73)Â Â Â â€‹Â 50â€‹Interest expenseâ€‹â€‹ (1,044)â€‹â€‹â€‹â€‹ (825)â€‹â€‹â€‹â€‹ (219)â€‹Unrealized foreign exchange (loss)/gainâ€‹Â (17)Â Â Â â€‹Â 5Â Â Â â€‹Â (22)â€‹Interest incomeâ€‹Â 570Â Â Â â€‹Â 115Â Â Â â€‹Â 455â€‹Net lossâ€‹$ (5,553)Â Â Â â€‹$ (5,444)Â Â Â â€‹$ (109)â€‹â€”We reported net product sales for the three-month period ended June 30, 2024 of $7.3 million and gross profit of $6.7 million after applying cost of product sales of $0.6 million. â€‹â€”Research and development expenses increased by $0.15 million for the three months ended June 30, 2024, compared to the same period in 2023. Our research and development activities for this period consisted of costs associated with investigator initiated clinical trials. During the same period in 2023 and prior to approval of PEDMARKÂ®, manufacturing costs pertaining to PEDMARKÂ® were expensed to R&D expense in the period incurred, and following approval are reflected in inventory. Â â€‹â€”Selling and marketing expenses were $4.7 million for the three months ended June 30, 2024. Selling and marketing expenses include remuneration of our sales and marketing employees, dollars spent on marketing campaigns (sponsorships, trade shows, presentations, etc.), and any activities to support marketing and sales activities. â€‹â€”General and administrative expenses increased by $1.4 million compared to the same period in 2023, primarily due to an increase in consulting and professional costs and increased European pre-commercialization related expenses compared to same period in 2023.â€‹â€”Interest expense increased $0.2 million compared to the same period in 2023. This increase is associated with higher interest rates and higher debt levels as compared with the same period in 2023. â€”Additionally, we hold shares of Processa Pharmaceuticals, Inc. (â€œProcessaâ€) (NASDAQ: PCSA) which are marked to market each balance sheet date and unrealized gains or losses are recognized at that time. The value of the Processa shares held by the Company decreased for the three month period ending June 30, 2024, as compared with the same period in 2023. Other losses were driven mainly by unrealized losses related to our foreign currency transactions. We have vendors that transact in Euros, Great British Pounds and Canadian Dollars. â€”There was an increase of $0.02 million in other losses for the three months ended June 30, 2024, compared to the same period in 2023. Amortization expense is also a non-cash expense and relates to amortization of the deferred issuance costs of the loan facilities with Petrichor. Amortization expense decreased by $0.05 million for the three months ended June 30, 2023 compared to the same period in 2023. Interest income increased by $0.5 million for 28Table of Contentsthe three months ended June 30, 2024, compared to the same period in 2023. This was driven mainly by higher interest rates for the three months ended June 30, 2024 compared to the same period in 2023. Six months ended June 30, 2024 versus six months ended June 30, 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended â€‹Â Â Â Â â€‹Six Months Ended â€‹Â Â Â Â â€‹â€‹In thousands of U.S. DollarsÂ Â Â Â JuneÂ 30,Â 2024Â Â Â Â %Â Â Â Â Â Â JuneÂ 30,Â 2023Â Â Â Â %Â Â Â Â Â Â ChangePEDMARK product sales, netâ€‹$ 14,681Â Â Â â€‹$ 5,002Â Â Â â€‹$ 9,679Licensing revenueâ€‹â€‹ 17,958â€‹â€‹â€‹â€‹ â€”â€‹â€‹â€‹â€‹ 17,958Total revenueâ€‹â€‹ 32,639â€‹â€‹â€‹â€‹ 5,002â€‹â€‹â€‹â€‹ 27,637â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating expenses:â€‹Â â€‹Â Â Â â€‹Â â€‹Â Â Â â€‹Â â€‹Cost of product salesâ€‹â€‹ 1,158â€‹ 4%â€‹ 243â€‹ â€”%â€‹ 915Research and developmentâ€‹Â 160Â â€”%Â Â Â 12Â â€”%Â Â Â 148Selling and marketingâ€‹â€‹ 9,881â€‹ 41%Â Â â€‹ 4,871â€‹ 33%â€‹ 5,010General and administrationâ€‹Â 12,736Â 53%Â Â Â 9,812Â 66%Â Â Â 2,924Total operating expensesâ€‹Â 23,935Â 100%Â Â Â 14,938Â 100%Â Â Â 8,997Income/(loss) from operationsâ€‹Â 8,704Â Â Â â€‹Â (9,936)Â Â Â â€‹Â 18,640â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Unrealized loss on securitiesâ€‹â€‹ (11)â€‹â€‹â€‹â€‹ (30)â€‹â€‹â€‹â€‹ 19Amortization expenseâ€‹â€‹ (43)â€‹â€‹â€‹â€‹ (145)â€‹â€‹â€‹â€‹ 102Interest expenseâ€‹â€‹ (2,078)â€‹â€‹â€‹â€‹ (1,623)â€‹â€‹â€‹â€‹ (455)Unrealized foreign exchange lossâ€‹Â (55)Â Â Â â€‹Â 14Â Â Â â€‹Â (69)Interest income â€‹Â 767Â Â Â â€‹Â 224Â Â Â â€‹Â 543Net Income/ (loss)â€‹$ 7,284Â Â Â â€‹$ (11,496)Â Â Â â€‹$ 18,780â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€”The Company recorded net product sales of $14.7 million and $18.0 million in licensing revenue related to the Norgine transaction for the six-month period ended June 30, 2024, compared to $5.0 million in product sales and no licensing revenue for the same period in 2023. â€”Selling and marketing expenses include distribution costs, logistics, shipping and insurance, advertising, wages commissions and out-of-pocket expenses. The Company recorded $9.9 million in selling and marketing expenses for the six-month period ended June 30, 2024, compared to $4.9 million for the same period in 2023. The increase is largely related to increased payroll and additional marketing expenses in the comparable period as the Company focused on expanding our initial outreach to community oncology centers and the adolescent and young adult (AYA) population, who can greatly benefit from our treatments compared to the prior year.â€”There was a $3.0 million increase in general and administrative expenses for the six-months ended June 30, 2024, compared to same period in 2023. There was an increase in consulting and professional costs compared to same period in 2023 which is largely attributable to increased European pre-commercialization related expenses and expenses associated with the Norgine transaction. â€”The value of the Processa shares held by us declined by $0.02 million for six-months ended June 30, 2024. The shares declined in value by $0.03 during same period in 2023. We acquired the Processa shares on OctoberÂ 30, 2020. The Processa shares are marked to market at each balance sheet date with the resulting change in value being booked as an unrealized gain or loss.â€”Amortization expense decreased by $0.1 million for six-months ended June 30, 2024, over the same period in 2023. 29Table of Contentsâ€”Interest expenses increased by $0.5 million for the six-month ended June 30, 2024 compared to same period in 2023. The increase was driven mainly by higher average debt balances and higher interest rates on long-term debt. â€”Interest income increased by $0.5 million for the six-months ended June 30, 2024, as compared to same period in 2023, due to higher cash balances and higher rates on money market accounts for the comparable periods. Liquidity and Capital Resourcesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As ofâ€‹As ofSelected Asset and Liability Data (thousands):Â Â Â Â JuneÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Cash and equivalentsâ€‹$ 43,054â€‹$ 13,269Other current assetsâ€‹Â 19,118â€‹Â 13,589Current liabilitiesâ€‹Â 7,749â€‹Â 7,553Working capital (1)â€‹Â 54,423â€‹Â 19,305(1) [Current assets â€“ current liabilities]â€‹â€‹ â€‹â€‹â€‹ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Selected Equity:â€‹Â â€‹â€‹Â â€‹Common stock and additional paid in capitalâ€‹â€‹ 209,361â€‹â€‹ 206,380Accumulated deficitâ€‹Â (211,961)â€‹Â (219,245)Stockholdersâ€™ deficitâ€‹Â (1,357)â€‹Â (11,622)â€‹Cash and cash equivalents were $43.0 million as of June 30, 2024, and $13.3 million at December 31, 2023. The increase in cash and cash equivalents between June 30, 2024 and December 31, 2023 is the result of cash outlays for operating expenses related to the promotion of our product, small amounts of research and development and general and administrative expenses, which were offset by cash inflows of $43.2 million from Norgine licensing deal, cash collections on product sales of $4.4 million and cash inflows of $1.0 million from various option exercises. There was an increase of $5.5 million in other current assets between June 30, 2024, and December 31, 2023, and an increase in current liabilities of $0.2 million. The overall result was an increase in working capital of $35.0 million. The following table illustrates a summary of cash flows data for the six-month periods of June 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Selected Cash Flow Dataâ€‹Six Months Ended JuneÂ 30,Â (dollars and shares in thousands)â€‹2024â€‹2023Net cash provided by / (used)in operating activitiesâ€‹$ 30,660â€‹$ (9,523)Net cash provided by investing activitiesâ€‹Â â€”â€‹Â â€”Net cash provided / (used) by financing activitiesâ€‹Â (875)â€‹Â 707Net cash flowâ€‹$ 29,785â€‹$ (8,816)â€‹Net cash provided by operating activities for the six-month period ended June 30, 2024 and 2023, primarily reflected a net income of $7.2 million and a net loss of $13.3 million respectively. The six month income was adjusted for the add back of non-cash items consisting of $3.7 million and $3.8 million, respectively, in stock-based compensation expense, amortization of debt access fee of $0.7 million and $0.1 million, respectively, and addition of PIK interest of $0.8 million and zero, respectively, for the six months ended June 30, 2024, and 2023. For the six months ended June 30, 2024 there was an increase in other current assets of $5.5 million and $1.4 million during the same period in 2023. For the six months ended June 30, 2024, there was a net increase in current liabilities of $0.1 million, with a net decrease of $0.4 million during that same period in 2023. Six month cash flows provided by operating activities were $30.6 million and net cash flows used in operating activities were $9.5 million, respectively, for the periods ended June 30, 2024 and 2023. Â Net cash used by financing activities for the six months ended June 30, 2024, were $0.9 million and net cash provided were $0.7 million, respectively. Net cash flows from the six month period ended June 30, 2024 and 2023, were positive $29.7 million, and negative $8.8 million, respectively.We continue to pursue various strategic alternatives including collaborations with other pharmaceutical and biotechnology companies.Â Our projections of further capital requirements are subject to substantial uncertainty.Â Our working capital 30Table of Contentsrequirements may fluctuate in future periods depending upon numerous factors, including: our ability to obtain additional financial resources; our ability to enter into collaborations that provide us with up-front payments, milestones or other payments; progress or lack of progress in our preclinical studies or clinical trials; unfavorable toxicology in our clinical programs; our drug substance requirements to support clinical programs; change in the focus, direction, or costs of our research and development programs; headcount expense; the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our patent claims; competitive and technological advances; the potential need to develop, acquire or license new technologies and products; our business development activities; new regulatory requirements implemented by regulatory authorities; the timing and outcome of any regulatory review process; and commercialization activities, if any.Outstanding Share InformationOur outstanding share data as of June 30, 2024 and December 31, 2023 was as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â Â â€‹Outstanding Share Typeâ€‹2024â€‹2023Â Â Â Â ChangeCommon sharesâ€‹ 27,329â€‹ 26,411Â 918Warrants Â 150Â 150â€‹ â€”Stock optionsÂ 5,228Â 5,032â€‹ 196TotalÂ 32,707Â 31,593â€‹ 1,114â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Financial InstrumentsWe invest excess cash and cash equivalents in high credit quality investments held by financial institutions in accordance with our investment policy designed to protect the principal investment.Â At June 30, 2024, we had approximately $0.9 million in our cash accounts and $42.2 million in savings and money market accounts.Â While we have never experienced any loss or write down of our money market investments since our inception, the amounts we hold in money market accounts are substantially above the $0.25 million amount insured by the FDIC and may lose value.Our investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment.Â Investments may be made in U.S. or Canadian obligations and bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy.Â Securities must have a minimum DunÂ & Bradstreet rating of A for bonds or R1 low for commercial paper.Â The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted average time to maturity of twelveÂ months.Â This policy applies to all of our financial resources.Â The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments.Â Until we are cash flow positive from operations, we have chosen to avoid investments of a trading or speculative nature.We classify fixed income investments with original maturities at the date of purchase greater than threeÂ months which mature at or less than twelveÂ months as current.Â We carry investments at their fair value with unrealized gains and losses included in other comprehensive income (loss); however, we have not held any instruments that were classified as short-term investments during the periods presented in this Quarterly Report.Off-Balance Sheet ArrangementsSince our inception, we have not had any material off-balance sheet arrangements.31Table of ContentsContractual Obligations and CommitmentsNone, other than the OHSU Agreement, lease agreements, and severance amounts described in notes to our condensed consolidated financial statements contained elsewhere in this Quarterly Report.Critical Accounting Policies and EstimatesA summary of our critical accounting policies and use of estimates are presented in Part II, Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationâ€ of our Annual Report. There have been no material changes to our critical accounting policies and use of estimates during the six months ended June 30, 2024.â€‹Revenue RecognitionUnder Accounting Standards Codification (â€œASCâ€) 606, Revenue from Contracts with Customers, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company determines it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customerÍ¾ (ii) identify the performance obligation(s) in the contractÍ¾ (iii) determine the transaction priceÍ¾ (iv) allocate the transaction price to the performance obligation(s) in the contractÍ¾ and (v) recognize revenue when (or as) the Company satisfies its performance obligation(s). As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.Stock-based CompensationThe calculation of the fair values of our stock-based compensation plans requires estimates that require managementâ€™s judgments.Â Under ASC 718, the fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model. The valuation models require assumptions and estimates to determine expected volatility, expected life, expected dividends and expected risk-free interest rates. The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. The risk-free interest rate assumption was based on the yield on zero-coupon U.S. Treasury strips at the award grant date. We also used historical data to estimate forfeiture experience.Â In valuing options granted in the fiscalÂ years ended June 30, 2024, we used the following weighted average assumptions:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Valuation â€‹â€‹â€‹Assumptionsâ€‹Black-Scholes Model Assumptionsâ€‹JuneÂ 30,Â 2024â€‹Expected dividendÂ -%Risk free rateÂ 4.40 - 5.01%Expected volatilityâ€‹45-65%Expected lifeâ€‹1.5 - 6.0yearsâ€‹Common shares and warrantsCommon shares are recorded as the net proceeds received on issuance after deducting all share issuance costs and the relative fair value of investor warrants.Â Warrants are recorded at relative fair value and are deducted from the proceeds of common shares and recorded on the consolidated statements of shareholdersâ€™ equity (deficit) as additional paid-in capital.â€‹32Table of ContentsItem 3. Quantitative and Qualitative Disclosures about Market RiskNot applicable.Item 4. Controls and Procedures.(a)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Evaluation of Disclosure Controls and Procedures.The Companyâ€™s management, with the participation of our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the Companyâ€™s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of June 30, 2024. Â The Companyâ€™s disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports the Company files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms and that such information is accumulated and communicated to the Companyâ€™s management, including the Companyâ€™s Chief Executive Officer and Chief Financial Officer, to allow for timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, the Companyâ€™s management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and

procedures are met. Â Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Â In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints that require the Companyâ€™s management to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2024, the Company's disclosure controls and procedures were not effective because of a material weakness in the Company's internal control over financial reporting related to fees and allowances paid to distributors for distinct services.The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. The Company's management evaluated the effectiveness of its internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that evaluation, the Companyâ€™s management has concluded that, as of June 30, 2024, our internal controls over financial reporting were not effective because of the existence of a material weakness in internal control over financial reporting related to fees and allowances paid to distributors for distinct services.A material weakness is defined as a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim consolidated financial statements will not be prevented or detected on a timely basis.With respect to the fees and allowances paid to distributors for distinct services, the execution of the controls over the application of accounting literature did not operate effectively with respect to:â—Measurement and classification of fees paid to customers for distinct services under ASC 606 Revenue from Contracts with Customers.â—Measurement of services received and expensed in a reporting period, measurement of services that pertain to future periods, and the periods of attribution for those future services.33Table of ContentsThe Company is evaluating the material weaknesses and developing a plan of remediation to strengthen the effectiveness of the design and operation of its internal control environment. The remediation plan will include the following actions:â—Enhance the formality of its review procedures with respect to accounting for new contracts with customers.â—Strengthen the review process to improve the operation of accounting and review controls with respect to complex and non-recurring transactions, as well as those transactions that require significant estimates and judgments.â—Engaging additional service providers or hiring additional full-time employees may be necessary and advisable to address these weaknesses.The actions that the Company is taking are subject to ongoing senior management review as well as Audit Committee oversight. The Company is committed to maintaining a strong internal control environment and believes that these remediation efforts will represent significant improvements in its controls. The Company has started to implement these steps including hiring additional full-time employee to assist with technical accounting and financial reporting; however, some of these steps will take time to be fully integrated and confirmed to be effective and sustainable. Additional controls may also be required over time. Until the remediation steps set forth above are fully implemented and tested, the material weakness described above will continue to exist.(b)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Changes in Internal Control over Financial Reporting.The Company is in the process of implementing changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) but does not believe any of these changes, as of the period covered by this Quarterly Report on Form 10-Q has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.â€‹PART II: OTHER INFORMATIONItem 1. Legal Proceedings. For information about our legal proceedings, please see our Commitments and Contingencies footnote (Note 6) to our unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report.Item 1A. Risk Factors.Our Annual Report includes a detailed discussion of our risk factors under the heading â€œPART I, Item 1A â€“ Risk Factors.â€ You should carefully consider the risk factors discussed in our Annual Report, as well as other information in this Quarterly Report. Any of these risks could cause our business, financial condition, results of operations and future growth prospects to suffer. We are not aware of any material changes from the risk factors previously disclosed.Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.None.Item 3. Defaults Upon Senior Securities.None.Item 4. Mine Safety Disclosures.Not applicable.34Table of ContentsItem 5. Other Information.On August 13, 2024, we issued a press release announcing our financial results for the quarter ended June 30, 2024. A copy of the news release is attached to this Quarterly Report as Exhibit 99.1. The press release is being furnished and shall not be deemed to be filed for the purposes of SectionÂ 18 of the Securities Exchange Act of 1934 (the â€œExchange Actâ€), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.â€‹ItemÂ 6. Exhibitsâ€‹ExhibitNo.Â Â Â Â Descriptionâ€‹â€‹â€‹31.1â€‹Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).Â â€‹Â 31.2â€‹Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).Â â€‹Â 32.1â€‹Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).Â â€‹Â 99.1â€‹Press Release for Quarter Ended June 30, 2024 (filed herewith).â€‹â€‹â€‹101.INS*â€‹Inline XBRL Instance Documentâ€‹â€‹â€‹101.SCH*â€‹Inline XBRL Taxonomy Extension Schema Documentâ€‹â€‹â€‹101.CAL*â€‹Inline XBRL Taxonomy Extension Calculation Linkbase Documentâ€‹â€‹â€‹101.DEF*â€‹Inline XBRL Taxonomy Extension Definition Linkbase Documentâ€‹â€‹â€‹101.LAB*â€‹Inline XBRL Taxonomy Extension Label Linkbase Documentâ€‹â€‹â€‹101.PRE*â€‹Inline XBRL Taxonomy Extension Presentation Linkbase Documentâ€‹â€‹â€‹104â€‹Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)â€‹â€‹35Table of ContentsSIGNATURESPursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.â€‹Â Fennec Pharmaceuticals Inc.Â Â Â Date: August 13, 2024By:/s/ Rostislav RaykovÂ Â Rostislav RaykovÂ Â Chief Executive OfficerÂ Â (principal executive officer)Â Â Â Date: August 13, 2024By:/s/ Robert AndradeÂ Â Robert AndradeÂ Â Chief Financial OfficerÂ Â (principal financial and chief accounting officer)â€‹â€‹â€‹â€‹36Exhibit 31.1â€‹FENNEC PHARMACEUTICALS INCCERTIFICATIONâ€‹I, Rostislav Raykov, certify that:â€‹Â 1.I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2024 of Fennec Pharmaceuticals Inc.;Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â 3.Based on my knowledge, the unaudited interim condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:Â (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):Â (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: August 13, 2024â€‹â€‹Â By:/s/ Rostislav RaykovÂ Â Rostislav RaykovÂ Â Chief Executive Officerâ€‹Exhibit 31.2â€‹FENNEC PHARMACEUTICALS INC.CERTIFICATIONâ€‹I, Robert Andrade, certify that:â€‹0Â 1.I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2024, of Fennec Pharmaceuticals Inc.;Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â 3.Based on my knowledge, the unaudited interim condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:Â (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):Â (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹Date: August 13, 2024â€‹Â By:/s/ Robert AndradeÂ Â Robert AndradeÂ Â Chief Financial Officerâ€‹â€‹Exhibit 32.1â€‹CERTIFICATION PURSUANT TO18 U.S.C. Â§1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report of Fennec Pharmaceuticals Inc. (the â€œCompanyâ€) on Form 10-Q for the period ended June 30, 2024 (the â€œReportâ€), each of the undersigned, Rostislav Raykov, Chief Executive Officer of the Company, and Robert Andrade, Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:â€‹Â 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andÂ 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹Date: August 13, 2024â€‹Â By:/s/ Rostislav RaykovÂ Â Rostislav RaykovÂ Â Chief Executive Officerâ€‹â€‹Date: August 13, 2024â€‹Â By:/s/ Robert AndradeÂ Â Robert AndradeÂ Â Chief Financial Officerâ€‹Exhibit 99.1â€‹FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEâ€‹~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ â€‹~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ â€‹~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~â€‹~ Management to Host Conference Call Today atÂ 8:30 a.m. ETÂ ~ â€‹Research Triangle Park, NC, August 13, 2024Â â€“Â Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2024, and provided a business update. â€‹â€œWe continued to execute well in the second quarter and are encouraged by the early third quarter momentum of PEDMARKÂ® within the community oncology and the adolescent and young adult (AYA) population,â€ said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. â€œI am excited to join Fennec and take on the challenge of guiding the Company towards greater commercial success. We will focus on expanding our initial outreach to community oncology centers and the adolescent and young adult (AYA) population, who can greatly benefit from our treatments. By reaching more patients in these critical areas, I am confident that we can drive growth and make a significant impact in improving patient outcomes.â€ â€‹Recent Developments and Highlights:â€‹â—AppointedÂ Jeffery HackmanÂ as Fennecâ€™s New CEO and Board Member:Â Jeff has been appointed as the new Chief Executive Officer and a member of the Board of Directors. With a passion for patients and a track record of success, Jeff is poised to make an immediate impact by driving Fennecâ€™s strategic direction and leading the Company into its next exciting phase of growth. Rosty Raykov will continue to contribute as a member of the Board of Directors.Â â€‹â—NCCN AYA Guidelines Updated:Â The NCCN Adolescent and Young Adult (AYA) Guidelines have been modified to remove â€œpediatricâ€ specific wording. This change is instrumental in solidifying PEDMARK's position for access to a broader patient population to prevent ototoxicity, both with payers and providers.â€‹â—Participation in Key Scientific Meetings:Â During the second quarter, Fennec actively participated in key regional and national scientific meetings, including the American Society of Clinical Oncology (ASCO), the Advanced Practice Providers Oncology Summit (APPOS), and the Oncology Nursing Society (ONS) annual meetings. These engagements underscore our commitment to advancing oncology care and fostering strong relationships within the healthcare community.â€‹ â€‹Financial Results for the Second Quarter 2024â€‹â—Net Sales â€“ The Company recorded net product sales of $7.3 million for the three-month period ended June 30, 2024, compared to $3.3 million in net sales for the same period in 2023. â€‹â—Cash Position â€“ Cash and cash equivalents were $43.1 million on June 30, 2024. The increase in cash and cash equivalents between June 30, 2024, and December 31, 2023, is the result of approximately $43 million from the Norgine transaction and cash inflows from net sales offset by cash outlays for operating expenses related to the promotion of our product, selling and marketing expenses and general and administrative expenses. We anticipate that our cash, cash equivalents and investment securities as of June 30, 2024 will be sufficient to fund our planned operations for at least the next twelve monthsâ€‹â—Selling and Marketing Expenses â€“The Company recorded $4.7 million in selling and marketing expenses for the period ended June 30, 2024, compared to $2.3 million for the same period in 2023. The increase is largely related to additional selling and marketing expenses as the Company expanded its focus in the AYA and community oncology population during 2024.â€‹â—General and Administrative (G&A) Expenses â€“ G&A expenses increased by $1.4 million over the same period in 2023 to $6.9 million. There was an increase in consulting, and professional costs related to European pre-commercialization related expenses in the 2024 period over the comparable period. European related expenses are expected to wind down after Q2 2024 with the announcement of the Norgine transaction in March 2024. â€‹â—Net Earnings â€“ Net loss for the quarter ended June 30, 2024 was $5.6 million (basic and diluted loss of $0.20 per share) compared to a net loss of $5.4 million (basic and diluted loss of $0.21 per share) for the same period in 2023.â€‹Q2 2024 Conference Call Informationâ€‹Date: Tuesday, August 13, 2024Time: Â 8:30 a.m. ETLink: https://register.vevent.com/register/BI59b5706a6c00453a9eed343d4a210de9 â€‹To access the conference call, please register using https://register.vevent.com/register/BI59b5706a6c00453a9eed343d4a210de9. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennepharma.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the companyâ€™s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.â€‹Financial Update â€‹The selected financial data presented below is derived from our unaudited condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles. The complete unaudited condensed consolidated financial statements for the period ended June 30, 2024 and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com. All values are presented in thousands unless otherwise noted.Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Unaudited Condensed ConsolidatedStatements of Operations:(U.S. Dollars in thousands except share and per share amounts)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Endedâ€‹â€‹â€‹JuneÂ 30,Â â€‹JuneÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Revenueâ€‹â€‹â€‹â€‹â€‹â€‹â€‹PEDMARK product sales, netâ€‹$ 7,262â€‹$

3,325â€‹Licensing revenueâ€‹â€‹ â€”â€‹â€‹ â€”â€‹Total revenueâ€‹â€‹ 7,262â€‹â€‹ 3,325â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating expenses:â€‹Â Â Â â€‹Â Â Â â€‹Cost of products soldâ€‹â€‹ 608â€‹â€‹ 148â€‹Research and developmentâ€‹Â 157â€‹Â 8â€‹Selling and marketingâ€‹â€‹ 4,672â€‹â€‹ 2,340â€‹General and administrativeâ€‹Â 6,864â€‹Â 5,495â€‹â€‹â€‹Â Â Â â€‹Â Â Â â€‹Total operating expensesâ€‹Â 12,301â€‹Â 7,991â€‹Loss from operationsâ€‹â€‹ (5,039)â€‹â€‹ (4,666)â€‹â€‹â€‹Â Â Â â€‹Â Â Â â€‹Other (expense)/incomeâ€‹Â Â Â â€‹Â Â Â â€‹Unrealized foreign exchange loss â€‹â€‹ (17)â€‹â€‹ 5â€‹Amortization expenseâ€‹â€‹ (23)â€‹â€‹ (73)â€‹Interest incomeâ€‹Â 570â€‹Â 115â€‹Interest expenseâ€‹â€‹ (1,044)â€‹â€‹ (825)â€‹Total other expenseâ€‹Â (514)â€‹Â (778)â€‹â€‹â€‹Â Â Â â€‹Â Â Â â€‹Net lossâ€‹$ (5,553)â€‹$ (5,444)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Basic net loss per common shareâ€‹$ (0.20)â€‹$ (0.21)â€‹Diluted net loss per common shareâ€‹$ (0.20)â€‹$ (0.21)â€‹Weighted-average number of common shares outstanding basic â€‹â€‹ 27,297â€‹â€‹ 26,458â€‹Weighted-average number of common shares outstanding diluted â€‹Â 27,297â€‹Â 26,458â€‹â€‹â€‹â€‹â€‹Fennec Pharmaceuticals Inc.Balance Sheets(U.S. Dollars and shares in thousands)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Unauditedâ€‹Unauditedâ€‹â€‹JuneÂ 30,Â â€‹December 31,â€‹â€‹2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹Assetsâ€‹â€‹Â Â Â â€‹Â Â â€‹â€‹â€‹Â Â Â â€‹Â Â Current assetsâ€‹â€‹Â Â Â â€‹Â Â Cash and cash equivalentsâ€‹$ 43,054â€‹$ 13,269Accounts receivable, netâ€‹â€‹ 12,312â€‹â€‹ 8,814Prepaid expensesâ€‹Â 4,379â€‹Â 2,575Inventoryâ€‹â€‹ 2,144â€‹â€‹ 2,156Other current assetsâ€‹Â 283â€‹Â 44Total current assetsâ€‹â€‹ 62,172â€‹â€‹ 26,858â€‹â€‹â€‹â€‹â€‹â€‹â€‹Non-current assetsâ€‹â€‹â€‹â€‹â€‹â€‹Other non-current assets, net amortizationâ€‹â€‹ 989â€‹â€‹ 6Total non-current assetsâ€‹â€‹ 989â€‹â€‹ 6Total assetsâ€‹$ 63,161â€‹$ 26,864â€‹â€‹Â Â Â â€‹Â Â Â Liabilities and shareholdersâ€™ deficitâ€‹Â Â Â â€‹Â Â Â â€‹â€‹Â Â Â â€‹Â Â Â Current liabilities:â€‹Â Â Â â€‹Â Â Â Accounts payableâ€‹$ 4,447â€‹$ 3,778Accrued liabilitiesâ€‹Â 3,038â€‹Â 3,754Operating lease liability - currentâ€‹â€‹ 12â€‹â€‹ 21Contract liability - Norgineâ€‹â€‹ 252â€‹â€‹ â€”Total current liabilitiesâ€‹Â 7,749â€‹Â 7,553â€‹â€‹â€‹â€‹â€‹â€‹â€‹Long-term liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹Term loanâ€‹â€‹ 30,000â€‹â€‹ 30,000PIK interestâ€‹â€‹ 2,022â€‹â€‹ 1,219Debt discountâ€‹â€‹ (247)â€‹â€‹ (288)Operating lease liability - net of current portionâ€‹â€‹ â€”â€‹â€‹ 2Contract liability - Norgineâ€‹â€‹ 24,994â€‹â€‹ â€”Total long-term liabilitiesâ€‹â€‹ 56,769â€‹â€‹ 30,933Total liabilitiesâ€‹Â 64,518â€‹Â 38,486â€‹â€‹Â Â Â â€‹Â Â Â Shareholdersâ€™ deficit:â€‹Â Â Â â€‹Â Â Â Common stock, no par value; unlimited shares authorized; 27,329 shares issued and outstanding (2023 â€‘27,027)â€‹Â 145,281â€‹Â 144,307Additional paid-in capitalâ€‹Â 64,080â€‹Â 62,073Accumulated deficitâ€‹Â (211,961)â€‹Â (219,245)Accumulated other comprehensive incomeâ€‹Â 1,243â€‹Â 1,243Total shareholdersâ€™ deficitâ€‹Â (1,357)â€‹Â (11,622)Total liabilities and shareholdersâ€™ deficitâ€‹$ 63,161â€‹$ 26,864â€‹â€‹â€‹Working Capitalâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Working capital â€‹Fiscal Period EndedSelected Asset and Liability Data:Â Â Â Â â€‹JuneÂ 30,Â 2024Â Â Â Â â€‹December 31, 2023(U.S. Dollars in thousands)â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash and equivalentsâ€‹$ 43,054â€‹$ 13,269Other current assetsâ€‹Â 19,118â€‹Â 13,589Current liabilities â€‹Â 7,749â€‹Â 7,553Working capital â€‹$ 54,423â€‹$ 19,305â€‹â€‹â€‹ â€‹â€‹â€‹ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Selected Equity:â€‹Â â€‹â€‹Â â€‹Common stock and additional paid in capitalâ€‹â€‹ 209,361â€‹â€‹ 206,380Accumulated deficitâ€‹Â (211,961)â€‹Â (219,245)Shareholdersâ€™ (deficit) equityâ€‹Â (1,357)â€‹Â (11,622)â€‹About Cisplatin-Induced Ototoxicity Cisplatin and other platinum compounds are essential chemotherapeutic agents for the treatment of many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to the survivors of pediatric cancer.iâ€‹The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.ii Infants and young children that are affected by ototoxicity at critical stages of development lack speech and language development and literacy, and older children and adolescents often lack social-emotional development and educational achievement.iiiâ€‹PEDMARKÂ® (sodium thiosulfate injection)PEDMARKÂ® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. Â â€‹In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.â€‹PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.â€‹â€‹Indications and UsagePEDMARKÂ® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.â€‹Limitations of UseThe safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.â€‹Important Safety Information Â PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.â€‹Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.â€‹PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.â€‹Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.â€‹Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m2.â€‹Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.â€‹The most common adverse reactions (â‰¥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (â‰¥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.â€‹Please see full Prescribing Information for PEDMARKÂ® at: www.PEDMARK.com.About Fennec PharmaceuticalsFennec Pharmaceuticals Inc.Â is a specialty pharmaceutical company focused on the development and commercialization of PEDMARKÂ®Â and PedmarqsiTM to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval inÂ September 2022Â and European Commission Marketing Authorization inÂ June 2023Â for Pedmarqsi. PEDMARK has received Orphan Drug Exclusivity in theÂ U.S.Â for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization inÂ EuropeÂ which includes eight years plus two years of data and market protection. Fennec has a license agreement withÂ Oregon Health and Science UniversityÂ (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com. Forward Looking StatementsExcept for historical information described in this press release, all other statements are forward-looking. Words such as â€œbelieve,â€ â€œanticipate,â€ â€œplan,â€ â€œexpect,â€ â€œestimate,â€ â€œintend,â€ â€œmay,â€ â€œwill,â€ or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline, and other goals, plans and prospects, including our commercialization plans respecting PEDMARKÂ®, the market opportunity for and market impact of PEDMARKÂ®, its potential impact on patients and anticipated benefits associated with its use, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Companyâ€™s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Companyâ€™s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Companyâ€™s products will not be as large as expected, the Companyâ€™s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Companyâ€™s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2023. Fennec disclaims any obligation to update these forward-looking statements except as required by law.â€‹For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.PEDMARKÂ® and FennecÂ® are registered trademarks of Fennec Pharmaceuticals Inc.Â©2024 Fennec Pharmaceuticals Inc. All rights reserved.Â For further information, please contact:Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.(919) 246-5299â€‹Media:Elixir Health Public RelationsLindsay Rocco(862) 596-1304lrocco@elixirhealthpr.comi Rybak L. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Current Opinion in Otolaryngology & Head and Neck Surgery. 2007, Vol. 15: 364-369.ii Landier W. Ototoxicity and Cancer Therapy. Cancer. June 2016 Vol. 122, No.11: 1647-1658.iii Bass JK, Knight KR, Yock TI, et al. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report from the Children's Oncology Group. Pediatric Blood & Cancer. 2016 Jul;63(7):1152-1162.